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Abstract
MicroRNAs (miRNAs) are endogenous small non-coding RNAs that have been
shown  to  play  important  roles  in  tumorigenesis.  Brucein  D  (BD),  a  chemical
compound isolated from Brucea javanica fruit, has previously been reported to have
anti-cancer  effect  in  pancreatic  cancer.  In  this  study,  we  showed  that  BD  also
inhibited the growth of liver cancer cells both in vitro and in vivo. To investigate
whether  BD  exerts  its  anti-cancer  effect  through  regulation  of  miRNAs,  we
performed a cancer miRNA qPCR array profiling. From the profiling, miR-95 was
found to be significantly down-regulated after BD treatment. Subsequently, a pro-
apoptotic gene CUGBP2 was identified as a direct downstream target of miR-95.
These findings  suggested BD suppressed liver  cancer  cell  growth through down-
regulation of miR-95 and reinforcing CUGBP2.
Pancreatic cancer is an aggressive malignancy with extremely poor prognosis. It
is usually diagnosed when metastases are already present. To identify genes that play
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critical roles in the processes of pancreatic cancer metastasis, a whole genome RNAi
screening  was  performed.  An  shRNA  library  targeting  all  human  genes  was
introduced into a human pancreatic cancer cell line capan-2. The infected cells were
then  transplanted  into  the  pancreas  of  nude  mice.  Because  capan-2  is  of  low
metastatic potential, we hypothesized that knocking down of metastasis suppressor
genes  would facilitate  capan-2  cells  to  spread to  the  liver.  By retrieving shRNA
templates from the liver metastatic nodules, several candidate genes were found. One
of them, SOX9, has been validated as metastasis suppressor gene in vivo, implying
that loss of expression of SOX9 promotes pancreatic cancer metastasis.
Chemotherapy is recommended for patients of pancreatic cancer in advanced
stage. However, their response to the first-line chemotherapy drug gemcitabine is not
satisfactory. A genome-wide RNAi screening was conducted to identify genes that
were critical in chemotherapy resistance. Capan-2 cells containing the above shRNA
library  were  applied  for  the  screening  under  gemcitabine  treatment.  Through
microarray  analysis,  a  number  of  genes  were  screened  as  potential  gemcitabine
sensitivity genes. Validation experiments implied that the gene LLGL1 may play an







定量 PCR阵列谱分析。此阵列包括 95个已被报道与肿瘤有关的微小 RNA。通过
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VIII
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TGF- β Transforming growth factor beta
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Liver cancers or hepatic cancers refer to all the malignant tumors growing in
the  liver.  Cancers  that  originate  from  liver  tissues  are  primary  liver  cancer.
Comparatively, cancers that derive from other organs of the body and spread to the
liver are metastatic liver cancer.
According to the cellular origin of cancer, primary liver cancer can be classified
as several subtypes. The cancer develops from hepatocytes is named hepatocellular
carcinoma (HCC), which represents the majority of primary liver cancer. The second
most common type is intrahepatic cholangiocellular carcinoma (ICC), which arises
from  biliary  epithelium.  Other  rarer  types  include  angiosarcoma  (or
heamangiosarcoma), which starts in the blood vessels of the liver, hepatoblastoma,
and lymphoma of liver.
Epidemiology
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By world area, liver cancer is the fourth most common cancer and the second
leading cause of cancer related death in men  (Jemal,  2007).  The annually rising
number of new cases and cancer deaths puts liver cancer as an important health
issue. In 2008, there were approximately 748,300 new cases diagnosed and 695,900
cases  died  from  it  (Ferlay,  2010).  The  distribution  of  HCC  by  geography  is
noticeably uneven. It is higher in less developed areas than in more developed areas.
Approximately 80% of HCC occurs in eastern Asia and sub-Saharan Africa (Parkin
2006). Specially, China accounts for about half of the cases.
In  the  high-risk  regions,  the  age  of  liver  cancer  incidence  shifts  towards
younger persons. In southeast Asia and west Africa, the incidence rate starts to rise
at the age of 20 to 30 years and reaches the peak at 50 years old. In the US and
European countries, the rate increases after 45 and stabilizes at around 65 years old
(Parkin  1992).  Men  are  more  likely  to  be  affected  by  liver  cancer,  which  is
consistent worldwide. The ratio of gender-specific incidence ranges from 1.4 to 3.3
(man/woman).  In  the more prevalent  districts,  higher  gender  ratios  are  observed
(Ferlay, 2001).
HCC is the most common type of primary liver cancer,  which accounts for
about 80% of all primary liver cancer cases globally (Perz, 2006). About one or two
out  of ten cases of primary liver cancer  is  diagnosed as ICC  (Shin,  2010).  This
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pattern is similar across different gender or ethnic groups.  In Chinese population,
however,  the proportion of HCC among all primary liver cancer cases can reach
95%. 
Etiology
HCC is  one  of  the  few  cancers  whose  risk  factors  and  causal  factors  are
relatively clearly established. The geographic variance of incidence reflects several
different causes of HCC (Bosch, 1999). In developing countries, hepatitis B virus
(HBV) infection is proved to be the major cause. Higher HBV infection prevalence
accompanies with higher incidence rate of HCC. In endemic areas where the carrier
rate  can  be  as  high  as  10–20%  of  the  whole  population,  over  60%  HCC  is
responsible for chronic HBV infection (Parkin, 2006). HBV carriers have 100-fold
higher probability than non-carriers to develop HCC. Infection of HBV at birth or
childhood results in HCC at early age. Additionally, introduction of HBV vaccine
into infants successfully  prevented the cases of HBV infection and incidence of
HCC  in  Taiwan  (Beasley,  1981).  Aflatoxin  B1  (AFB)  intake  from  diet  also
contributes to HCC in less developed areas (Ming, 2002).
In western countries and Japan, where HBV infection is rare, hepatitis C virus
(HCV) infection is proved to be the main risk factor(Bosetti, 2008; Altekruse, 2009).
The recently elevated incidence of HCC in the low-risk areas is probably due to the
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dissemination  of  HCV  through  blood  transfusion  by  drug  abusers.   Causes  of
cirrhosis such as alcohol and non-alcohol fatty liver disease associated with obesity
are also closely linked with HCC in developed countries. (El-Serag, 2007)
Given the prevalence of HBV infection and continuously high HCC incidence
rate in Africa and Asia, and the growing number of new cases of HCC in US and
Europe, the prevention and management of HCC are always urgent problems that
need intensive investigation (Schwartz, 2011).
Molecular pathogenesis of HCC 
Our current understanding of the molecular mechanisms that give rise to HCC
mainly concludes  the  genetic  alteration,  deregulation  of  signaling  pathways,  and
aberrant epigenetic modifications. In general, HCC is a result of both genetic and
epigenetic  changes  that  accumulatively  lead  to  the  transformation  of  normal
hepatocytes  into  malignant  cells.  Additionally,  two  diverse  yet  complimentary
models  of  HCC  tumorigenesis  have  been  established,  which  will  improve  our
understanding in this field as well (Kumar, 2011).
Genomic instability
It has been shown that regions of 1p, 4q, 6q, 8p, 9p, 13q, 16p, 16q and 17p are
most frequently lost and regions of 1q, 6p, 8q and 17q are most commonly gained
by comparing large scale of HCC tumors and non-tumorous tissue  (Homayounfar,
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2009). The deleted chromosome regions correlate with mutation or deletion of tumor
suppressor genes (TSG) such as TP53, insulin-like growth factor-2 receptor IGF-2R,
CDKN2A (p16INK4A), and retinoblastoma RB1 (Rb) (Kumar, 2011).
TP53  gene  encoding  the  p53  protein  actively  exerts  its  tumor  suppressive
function  in  the  presence  of  varies  cellular  stress,  resulting  in  cell  cycle  arrest,
apoptosis, or senescence. HCC is commonly linked with TP53 deletion or loss of
function mutation in  chromosome 17p  (Hussain,  2006).  A particular  mutagen of
TP53 is AFB1, whose intake from food is highly correlated with HCC incidence
(Aguilar, 1993). A viral protein HBx coding by HBV can specifically bind to p53
and thus blocks p53-mediated apoptosis (Wang, 1994).
Deregulation of key signaling pathways
Several signaling pathways that are important in carcinogenesis are found to be
activated in HCC. Deregulation of these pathways plays an important role in HCC
pathogenesis.
Inactivation of the transforming growth factor-β (TGF-β) signaling is another
common molecular event in HCC. The role of TGF- β is controversial. It induces
apoptosis and cell cycle arrest in normal conditions and early stages of cancer. In
advanced stages, TGF- β in return losses its control of cell proliferation. It has been
observed  that  HCC  is  associated  with  disrupted  TGF-β  signaling  together  with
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interleukin-6  (IL-6)  signaling  activation  (Tang,  2008).  And  alteration  of
glycoprotein-130 (gp130), a co-receptor of IL-6, is also accompanied with β-catenin
activating mutation in HCC (Rebouissou, 2009). All of these factors interplay with
each other to contribute to HCC tumorigenesis.
The  Wnt/  β-catenin  pathway  plays  an  important  part  in  development,  cell
differentiation, and proliferation. Without Wnt signaling, β-catenin binds with the
tumor suppressor adenomatosis polyposis coli (APC), Axin1, and glycogen synthase
kinase-3β  (GSK-3β)  in  cytoplasm.  GSK-3B  sends  β-catenin  to  ubiquitin  for
degradation.  When  Wnt  signaling  participates,  conformational  change  of  Axin
releases β-catenin.  Subsequently β-catenin translocates into nucleus and activates
oncogenic Myc, which bypasses cell senescence through induction of telomerase.
An elevated level of Wnt signaling is observed in HCC. Probably these pathways are
also  responsible  for  carcinogenesis  of  HCC  (Cavard,  2008).  Wnt/  β-catenin
signaling  also  activates  PI3K/PTEN/Akt  pathway.  Activation  of  Akt  signaling  is
associated  with  more  aggressive  HCC  (Nakanishi,  2005).  There  may  be  some
interaction between PI3K/PTEN/Akt and Wnt/β-catenin pathways to promote HCC
progression.
Epigenetic changes of HCC
In  addition  to  genetic  abnormalities,  epigenetic  changes  contribute  to  HCC
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occurrence as well. In the past decade, growing evidence supports that altered DNA
methylation is responsible for human HCC. DNA methylation refers to a methyl
group (-CH3) being covalently bonded to the 5-carbon of a cytosine. In human 90%
cytosine methylation is found at dinucleotide CpG sequences  (Tykocinski, 1984).
Among them, promoter CpG islands, which is defined as regions larger than 200bp
with  more  than  50%  GC  content,  are  the  most  frequent  sites (Jones,  2002).
Expression  of  a  gene  is  controlled  by  its  promoter  DNA methylation  status.
Basically, promoter methylation silences the expression of a gene, and vice versa
(Larsen,  1992).  Thus  hypermethylation  of  a  TSG  may  lead  to  malignant
development. On the contrary, hypomethylation of oncogenes favors tumorigenesis.
Accumulative studies show that aberrant DNA methylation is found in various types
of cancer, including HCC (Jones, 2002).
Two models of HCC pathogenesis
The pathogenesis of HCC can be explained by two prevalent models (Kumar,
2011). The first model illustrates the development of HCC as a stepwise process.
Malignancy occurs from normal hepatocytes to dysplastic nodules, and precancerous
lesions,  and  finally  tumor  cells.  The  process  is  a  consequence  of  accumulative
genetic and epigenetic alterations. The previous described etiological factors such as
hepatitis viruses and AFB1 contributes to these changes. And every single tumor cell
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is regarded as monoclonal origination. This model is fine except that it could not to
be efficiently translated into useful approaches to address the problems in current
HCC therapies.
More recently another model sheds new lights on our understanding of HCC
development. Given that liver is a regenerative organ, the self-renewal and unlimited
dividing progenitor liver cells that differentiate into hepatocytes can also develop
into  HCC.  It  is  hypothesized  that  HCC  is  possibly  derived  from  transformed
progenitor  cells.  This  cancer  stem  cell  model  does  not  conflict  the  multistep
hypothesis. In turn, it offers a more comprehensive explanation of the generation of
HCC. What’s more, based on this model, clinical treatments targeting hepatocytes
possessing stemness nature will be a more beneficial choice.
Therapeutic methods and prognosis of HCC 
Current  management  for  HCC  includes  curative  treatment  and  palliative
treatment  (Llovet,  2003).  Generally  30% to  40% HCC patients  receive  curative
treatment.  The  methods  of  curative  treatment  contain  surgical  resection,
percutaneous ablation and liver transplantation. Surgery is considered the treatment
of choice for HCC, and a considerable number of patients get satisfactory responses
after resection. But only a limited number of cases are surgical resectable. More
common situations are that diagnosis is made when metastasis is already present.
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Patients who should be given curative treatment must be carefully selected regarding
their disease staging. On the other hand, good as liver transplantation is, the long
waiting time for a donor liver restrains the application of liver transplantation to cure
HCC.  However,  tumor  recurrence  always  exists,  further  rendering  the  disease
complicated to eradicate. If no better option comes out, current methods only benefit
a small population.
Palliative treatment, such as arterial embolization, chemotherapy and oestrogen
blockade, is for advanced stages. Patients who are not suitable to receive curative
treatment  will  be  given  palliative  treatment.  Nevertheless,  the  inclusion  criteria
should  also  be  strictly  defined.  From  several  randomized  control  trials,  no
significant survival benefit was observed among these methods.
In general, current therapeutic methods are far from satisfactory to meet our
needs. Developing novel effective strategies for HCC treatment is of great concern.
Apoptosis
Types of cell death
When  a  cell  is  going  to  die,  there  are  some  molecular  and  morphological
changes  occurring:  loss  of  membrane  integrity,  fragmentation  of  the  cell,  and
engulfment  of  the  fragments  by  adjacent  cells.  According  to  the  morphological
characteristics,  cell  death  can  be  divided  as  apoptosis,  necrosis,  autophage,  and
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mitosis.  Based  on  the  functional  criteria,  there  are  programmed  cell  death  and
accidental cell death. 
Apoptosis
The  term  “apoptosis”  described  a  specific  type  of  cell  death  in  its
morphological aspects. Defects occurring at any point of the regulatory pathways of
apoptosis cause a variety of problems. For instance, too much apoptosis results in
degenerative diseases, while too little leads to uncontrolled cell growth including
cancer. Complicated as the mechanisms are, unraveling the control of apoptosis will
extend its significance for not only understand the pathogenesis of a disease, but also
novel strategies for cancer therapies. 
Morphological features of apoptosis
In contrast  to  necrosis,  cells  undergo apoptosis  actively switch  on a  course
towards death. Morphological changes of apoptosis includes rounding up of cells,
retraction of pseudopods, reduced cell volume, and, the most importantly, chromatin
condensation and nuclear fragmentation (Kroemer, 2005). On the biochemical bases,
membrane changes, breakdown of DNA and proteins, and activation of caspases are
three  hallmarks  of  apoptosis  (Robbins,  2009). In  early  stage  of  apoptosis,
phosphatidylserine (PS) translocates from the inner layers of the cell membrane to
the  outer  layer,  allowing  recognition  by  macrophages  for  phagocytosis  without
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inflammation reactions (Hengartner, 2001). Later on, it comes to the breakdown of
DNA into large fragments and then the cleavage of DNA into multiple small pieces
of 180 to 200 bp by endonucleases (McCarthy, 1998). But DNA fragmentation is not
specific  to  apoptosis,  which  can  also  be  seen  in  necrosis.  Another  feature  of
apoptosis  is  the  activation  of  caspases,  which  are  a  group  of  cysteine  protease
catalyzing aspartic acid residues. They destroy many pivotal proteins of the cell and
activates DNAase for DNA degradation(Lavrik, 2005). However, apoptosis could be
caspase-independent as well.
Molecular mechanisms of apoptosis
Caspases are the central  players of apoptosis  for they initiate and guide the
process of apoptosis. Three pathways that activate caspases are (1) intrinsic pathway
or mitochondrial pathway; (2) extrinsic pathway or death receptor pathway; and (3)
intrinsic endoplasmic reticulum (ER) pathway (Wong, 2011).
The extrinsic death receptor pathway is activated upon external damage stimuli
by the binding of death ligands, such as Fas ligand (FasL) and TNF, to their death
receptor  (Hengartner 2001). This binding induces the formation of death-inducing
signaling  complex  (DISC),  which  then  assembles  and  activates  pro-caspase  8.
Subsequently, the caspase initiator, caspase-8, starts the progression of apoptosis by
activating other downstream caspases (Reed, 2000)
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Intrinsic mitochondrial pathway is triggered by internal stimuli,  for example
genetic damage, hypoxia, and oxidative stress. Mitochondrial permeability initiates
the pathway (Danial, 2004). Bcl-2 family proteins play a major part in the process.
Bcl-2 family can be divided into two groups, the pro-apoptotic proteins (Bax,Bak,
Bad, Bcl-Xs, Bid, Bik, Bim, and Hrk) and the anti-apoptotic proteins (Bcl-2, Bcl-Xl,
Bcl-W, Bfl-1, and Mcl-1) (Reed, 1997). Pro-apoptotic proteins promote the release
of  cytochrome-c  from mitochondrial.  On  the  other  hand,  anti-apoptotic  proteins
block  the  release.  The balance  between the  two groups  of  proteins  controls  the
initiation of intrinsic apoptosis. The release of cytochrome c induces the formation
of  apoptosome,  which  contains  cytochrome  c,  Apaf-1,  and  caspase-9,  and  then
activates of caspase-3 (Kroemer, 2007).
The activation of upstream caspases, caspase-8 and caspase-9 of extrinsic and
intrinsic  pathways  respectively,  converge  to  activate  caspas-3.  Caspase-3  then
induces the cleavages of the inhibitor of the caspase-activated deoxyribonuclease for
nuclear apoptosis.  Other downstream proteins catalyzes more vital cellular proteins
relating  with  cytoskeleton  and  cell  cycle,  finally  leading  to  the  apoptotic
morphological changes (Ghobrial, 2005). 
The intrinsic endoplasmic reticulum pathway is not well studied. When cellular
stresses pose injuries to the ER, protein synthesis reduces and some proteins unfold.
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TNF receptor associated factor 2 (TRAF2) leaves pro-caspase-12. Here comes the
activation of intrinsic ER pathway (Szegezdi, 2003).
Apoptosis and cancer
Basically, decreased level of apoptosis leads to tumorigenesis. Cells that are
less apoptotic or resistant to apoptosis and thus acquiring malignant transformation
can be accessed by several ways. In general there are three ways: (1) breakdown of
the balance between pro-apoptotic preteins and anti-apoptotic proteins; (2) loss of
functional caspases; and (3) disruption of death receptor signaling pathways. 
Imbalance of pro-apoptotic proteins and anti-apoptotic proteins
Based on their functions in cells, some proteins are regarded as pro-apoptotic
proteins or anti-apoptotic proteins. The normal ratio of these proteins plays a vital
role in determining cell proliferation or cell death. Overexpression of anti-apoptotic
proteins  and  under-expression  of  pro-apoptotic  proteins  lead  to  reduction  of
apoptosis, and thus confer to carcinogenesis. 
The  Bcl-2  protein  family  contains  both  pro-apoptotic  and  anti-apoptotic
proteins. They mainly act through the intrinsic pathway due to their location on the
outer layer of mitochondrial membrane  (Gross, 1999). Disrupted balance between
anti-apoptotic and pro-apoptotic proteins of the Bcl-2 family has frequently been
reported to result in deregulated apoptosis.  Overexpression of Bcl-2 protected cells
13
from  apoptosis  in  prostate  cancer  (Raffo,  1995),  neuroblastoma,  and  breast
cancer(Fulda, 2000).  Overexpression of Bcl-xL is reported to associate with drug
resistance  (Fulda,  2002).  Mutation  of  bax  is  common  in  colorectal  cancers  and
endows colorectal cells resistance to anticancer therapy (Miquel, 2005). 
The protein p53 or tumor protein 53 (TP53) is another key player in apoptosis.
Activation  of  tumor  suppressive  p53  promotes  transcription  of  pro-apoptosis
proteins and suppresses the transcription of anti-apoptotic proteins. Mutation of this
tumor suppressor gene renders the affected cells oncogenic (Okada, 2006).
The  inhibitor  of  apoptosis  proteins  (IAPs)  are  another  group  of  proteins
mediating  apoptosis,  cytokinesis  and  signal  transduction.  IAPs  are  endogenous
inhibitors  of  caspases  to  degrade  activated  caspases  or  prevent  caspases  from
binding to their substrates. IAPs implication has been reported in many cancers, for
instance, pancreatic cancer (Lopes, 2007), non-small cell lung carcinomas resistance
(Krepela, 2009), and melanoma (Vucic, 2000). 
Impaired caspases activity
Apoptosis  associated  caspases  can  be  divided as  initiator  caspases  (such as
caspase-2,  -8,  -9,  and -10) and effector  caspases (such as  caspase-3,  -6,  and -7)
which direct the cleavage of cellular components. Loss of functional caspases could
lead  to  eliminated  apoptosis  and  promotes  carcinogenesis.  Examples  are
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downregulation of caspase-9 in colorectal cancer (Shen, 2010), decreased caspase-3
level in breast, ovarian and cervical tumors (Devarajan, 2002), and low expression
of caspase-8 and -10 in choriocarcinoma (Fong, 2006).
Deregulated death receptor signaling
In  the  extrinsic  pathway,  death  receptor  pathway  plays  an  important  part.
Triggered by a death signal, the death receptors (such as TNFR1 or DR1, Fas or
DR2) attract a variety of cellular molecules to their death domains and thus initiate
the signaling cascade. Any abnormalities involved in the death signaling can result
in a reduction of apoptosis and may be responsible for carcinogenesis.
Cancer therapy targeting apoptotic defects
Fortunately, the mechanisms of defects in apoptosis just provide us therapeutic
target for cancer treatment. Any strategies that can revise the balance of apoptotic
signaling exert  the potential  to  treat  cancer.  Currently,  several  methods targeting
defects  in  apoptosis  have  been  investigated.  In  general,  gene  therapy,
immunotherapy and drug therapy are the novel options. The most popular molecules
being the targets include the anti-apoptotic proteins in the Bcl-2 family,  the p53
gene, Survivn, XIAP, and caspases.  A number of them achieve benefits in cell-based
experiments and animal models. Some of them have already entered different stages
of  clinical  trials.  The  problems  to  be  considered  mainly  focus  on  whether  the
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treatment causes massive death of normal cells, whether resistance will be induced.
If the therapy specifically targets a single protein or only one pathway, it would be
more beneficial.  The combination of molecular therapy and conventional therapy
may possess broader applications.  Nevertheless,  long-term clinical observation is
needed and future investigations should aim at the selectivity of the treatment to
induce apoptosis in cancer cells but not normal cells.
microRNA
Overview
Implications of microRNA (miRNA) in biological processes and diseases have
drawn increasing  attention  from scientists.  They are  a  collection  of  endogenous
small RNAs. They are generated from endogenous transcripts. The mature form of
miRNAs  are  of  about  19  –  25  nucleotides  in  length.  They  bind  to  their  target
mRNAs in a sequence specific manner and then mediate gene silencing at  post-
transcriptional and translational levels. Since the first two miRNAs, lin-4 and let-7,
were discovered in Caenorhabditis elegans, hundreds of thousands of miRNAs have
been identified in various species. Bioinformatic analysis predicts more than 1000
miRNAs existing in human genome. Subsequent studies have revealed that miRNAs
are involved in  most  biological  processes  and the aberrant  expression pattern of
miRNAs  has  been  implicated  in  numerous  diseases.  The  discovery  of  the
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mechanisms of miRNAs’ part taking in gene regulation has opened up exciting era
for future researches. 
Biogenesis and maturation of microRNA
Most human miRNA genes locate within introns of protein-coding genes or
intergenic regions of non-protein-coding genes in chromosomes. Their transcription
can be regulated by their  host gene promoters.  A large number of miRNAs are
found in clusters and are transcribed as polycistronic transcripts  (Lagos-Quintana,
2003). The first step of miRNA biogenesis is the generation of primary miRNAs
(pri-miRNAs).  This  process  is  transcribed  by RNA Polymerase  II  (Pol  II).  Pri-
miRNAs are about hundreds to thousands nucleotides in length containing stem-loop
structures together with the unique 7-methylguanosine caps and poly A tails.  (Cai,
2004; Lee,  2004).  In the next step,  pri-miRNAs are processed by two RNase-III
enzymes,  Drosha  and  Dicer.  Both  of  the  two  enzymes  are  double  strand  RNA
(dsRNA) specific. Localized in the nucleus, Drosha cleaves pri-miRNAs into about
70 bp fragments consisting of imperfect stem-loop structures, generating precursor
miRNAs  (pre-miRNAs)(Lee,  2004).  Following  the  cleavage  by  Drosha,  pre-
miRNAs are transported from nucleus into cytoplasm by Exportin-5 (Exp-5) (Lund,
2004).  As  soon  as  the  arrival  in  cytoplasm,  pre-miRNAs  are  catalyzed  by  the
cytoplasmic RNase III, Dicer. They are then cleavage into small imperfect dsRNAs,
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which is a miRNA : miRNA* duplex containing both the mature miRNA and its
complementary strand miRNA*. It is believed that miRNA* also takes part in gene
regulation, although the mature miRNA plays a more active role in gene silencing
(Tang, 2005). 
Gene silencing by microRNA
Gene silencing mediated by miRNAs requires the formation of the  miRNA-
containing  RNA-induced  silencing  complex  (miRISC).  The  mature  miRNA strand
released from the  miRNA : miRNA*  duplex incorporate into the miRISC complex,
while the miRNA* is rapidly degraded. The mature miRNA helps miRISC to recognize
its target genes by complementary binding to the 3’ untranslated regions (3’ UTR) of
target mRNAs (Bartel, 2004).
Suppression of gene expressions by miRNAs is carried out at post-transcriptional
level and translational level.  A well-studied model  is  illustrated by lin-4 and lin-14.
Perfect base-pairing between lin-4 and lin-14 is crucial for the negative regulation. Lin-
4 only inhibits lin-14 protein synthesis but fails to affect the mRNA abundance of lin-
14, implying a repression effect at translational levels (Olsen, 1999). This mechanism is
common among miRNAs in animals. Another model that has been established indicates
that  miRNA can  directly  induce  its  target  gene  mRNA destruction  (Yekta,  2004).
However, the mechanism of post-transcriptional suppression still needs to be elucidated.
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The miRISC mediated gene suppression also depends on the degree of complementarity
between the miRNA and its target sequences. Basically, perfect base-pairing between
the  mature  miRNA and target  gene 3’UTR sequences  favors  cleavage of the  target
mRNA.  Inhibition  of  translation  can  be  processed  in  partial  complementary  cases
(Bartel, 2004).
The sequence-specific recognition of miRNA to its target mRNA is determined by
a crucial region of miRNA. This region locates at 2 to 7 nucleotides from the 5’ end of
mature miRNA and is named “seed sequence” (Xie, 2005). Genomic analysis showed
that the seed sequences of a large number of miRNAs are complementary to the 3’UTRs
of various mRNAs. Moreover, it is found that one miRNA is able to target different
3’UTRs.  Meanwhile,  the  3’UTR  of  an  mRNA may  also  be  targeted  by  numerous
miRNAs.  Thus it  is  reasonable to  imagine  gene regulation on miRNA-mRNA basis
must be quite a complicated, yet precisely orchestrated, network of gene regulation. In
general,  miRNA mediated gene silencing relies  on the complementarity between the
seed sequence of miRNAs and the 3’UTRs of target mRNAs (Gregory, 2006).
MicroRNA and cancers
MiRNAs  participate  in  many  biological  processes,  including  development,
differentiation,  proliferation,  and  apoptosis  (Bartel,  2004).  Aberrant  expression  of
miRNAs  has  been  implicated  in  numerous  diseases,  including  cancer.  Abnormal
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expression patterns of miRNAs have been detected in  a number of types of human
cancers.  For example, reduced expression of miR-15 and miR-16-1 is tightly linked
with  chronic  lymphocytic  leukemia  (CLL)  (Cimmino,  2005).  A  single  nucleotide
polymorphism (SNP) is associated with poor outcome of non-small cell  lung cancer
(Hu,  2008).  MiRNAs’ association  with  cancer  can  be  either  oncogenesis  or  tumor
suppressive.  On the  one hand,  miRNAs’ location in  genomic regions  determines  its
nature of carcinogenesis.  When it  locates in regions that are frequently amplified in
cancers,  it  functions  as  oncogenic  miRNA.  Conversely,  if  a  miRNA  locates  in
chromosomes that are deleted in cancers, it acts as a tumor suppressor. On the other
hand, the function of a miRNA can be determined by its target gene that may be either
oncogenic or tumor suppressive. 
The use of miRNA in cancer management has been intensively explored recently.
Based on the changed pattern of miRNA expression in cancers, miRNA profiles may
assist  to  diagnose  cancer  types.  Based  on  its  endogenous  antisense  interaction  with
target  genes,  it  is  proposed  that  miRNAs  could  be  used  for  cancer  treatments.
Administration  of  ectopic  miRNAs  to  suppress  oncogene  is  also  promising
(McLaughlin, 2007; Liu, 2009) However, many problems are still needed to be tackled.
Besides the mechanisms of miRNA in cancer, some studies have focused on how to
enhance life time and efficiency of miRNAs in human body, such as modification of
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miRNA molecules. To bring theoretical concepts to bedside practice, there is still a long
way to go.  Nevertheless,  advances  in  understanding the miRNA mechanisms in
cancer will extend its potential application significance in cancer therapy.
MicroRNA’s involvement in HCC
Several miRNAs have been reported to have implications in HCC. For example,
miR-181 expression has been proved to be negatively correlated with Wnt/β-catenin
signaling in HCC. Elevated Wnt/β-catenin signaling is accompanied with increased
miR-181  expression.  Knocking  down  of  TGF-  β  is  associated  with  reduced
expression  of  miR-181  (Wang,  2010;  Ji,  2009).  Loss  of  let-7g  favors  HCC
metastasis (Ji, 2010), while some other miRNA expression profile is identified to be
related with venous metastasis  (Budhu, 2008). Cancer cells with silenced miR-26
undergo more active signaling pathways related to inflammation and have better
response to interferon therapy (Ji, 2009). MiR-21 expression is linked with loss of
heterozygosity of PTEN. As a consequence, Akt signaling pathway is activated, thus
enhancing tumorigenesis (Meng, 2007). MiRNA induced cell cycle deregulation and
prohibition of apoptosis have also been reported (Varnholt, 2008).
Involvement of miR-95 in cancer
Increasing findings support the notion that miR-95 functions as an oncogene in
cancers. From a miRNA profiling study comparing pancreatic cancer tissue samples
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with normal tissues, miR-95 was found to be up-regulated in both pancreatic cancer
surgical  specimens  and pancreatic  cancer  cell  lines  (Zhang,  2009).  In  colorectal
cancer (CRC), miR-95 also has increased expression.  (Huang, 2011) Inhibition of
miR-95 prohibited Hela cell growth (Cheng, 2005). Ectopic introduction of miR-95
in  human  CRC  cell  lines  enhances  both  in  vitro  cell  growth  and  in  vivo
tumorigenesis.  A tumor suppressor gene, SNX1 is identified as the down-stream
target of miR-95, further implying the oncogenesis nature of miR-95 (Huang, 2011).
However, to date, there has been relatively little research conducted on miR-95’s
implication in liver cancer.
Brucein D
Brucein  D (BD) is  a  naturally  occurring  chemical  compound  isolated  from
Brucea javanica fruit, which is commonly used in Chinese medicine to treat cancer.
The chemical structure of BD is demonstrated below (adapted from S.T. Lau, 2009). 
               
Previous  studies  demonstrate  that  BD exerts  cytotoxic  effect  on  pancreatic
cancer  cell  lines  by  inducing  apoptosis  and  cell  cycle  arrest  (Lau,  2009).  The
mechanisms  of  BD’s  being  an  apoptogenic  agent  of  pancreatic  cancer  involve
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activation of p38-MAPK pathway and inhibition of NF-κB anti-apoptotic activity




(1) BD had anti-cancer effect on HCC cells;
(2) BD could induce apoptosis to inhibit cell growth;
(3) BD could change expression pattern of miRNAs in HCC cells;
(4) BD could modulate cell growth by regulating expression of a specific miRNA
which executed its function through its downstream target gene. 
Our objectives were to
(1) Investigate whether BD exhibits anti-cancer effect for HCC cells;
(2) Examine whether BD induces apoptosis;
(3) Find different expression patterns of miRNAs before and after BD treatment in
HCC cells;
(4) Identify miRNA targets of BD and downstream genes of the targeted miRNAs 




Mammalian Cell Culture 
293T, MIHA, HepG2, Hep3B, Huh7, Bel7404 and PLC cells  were obtained
from the American Type Culture Collection (Rockville, MD, USA). The cells were
cultured  in  Dulbecco’s  modified  Eagle’s  medium supplemented  with  50  unit/ml
penicillin-streptomycin  (GibcoBRL,  USA)  and  10%  (v/v)  fetal  bovine  serum
(Hyclone) in a humidified incubator at  37°C in 5% CO2.  After the cells reached
about 80% confluence, the medium was removed and the cells were trypsinized with
1 ml of 0.05% trypsin-EDTA (Gibco, USA ) for 2 mins. Then cell suspension was
transferred to a 15-ml centrifuge tube containing 10 ml of PBS and centrifuged at
1,000 rpm at room temperature for 5 min. The cell pellet was resuspended with fresh
medium and transferred to new plates and incubated as described above. 
Preparation of cell stock 
When reached about 80% confluent, the cells were washed with PBS twice and
trypsinized as described above. After centrifugation, the cell pellet was resuspended
in a freezing medium (20% v/v FBS and 10% DMSO in DMEM) 450 µl of DMEM
supplemented with 10% v/v fetal bovine serum and transferred into a 2-ml freezing
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tube containing 450 µl of fetal bovine serum and 100 µl of DMSO. The medium was
transferred to a 2-ml freezing tube and put in an isopropanol filled freezing. Finally,
the pot was put into a -80°C freezer so that the cell stock was frozen at a constant
rate of about 1°C/min. Cell stocks were stored at -80°C or liquid nitrogen.
Cell recovery from liquid nitrogen stock 
The cell stock tube was taken out from the liquid nitrogen tank or -80°C freezer
which was immediately thawed in a 37°C water bath. To remove the DMSO, the cell
stock was diluted with 10 ml of DMEM with 10% v/v FBS. The cell suspension was
centrifuged as described above and the supernatant was discarded. The cell pellet
was resuspended in 10 ml of DMEM containing 10% FBS and plated on a 10-cm
tissue culture plate. One day after cell recovery, the medium was changed.
Preparation of drugs for treatments
Brucein D was provided by Professor Lin Zhixiu of the Chinese University of
Hong Kong. Its purity was above 98%. It was dissolved in steriled DMSO (Sigma-
Aldrich, USA) at the concentration of 100 mM and stored at 4°C. Right before use,
stock solution was further diluted in sterile DMEM to different final concentrations.
Stock solution of BD was aliquot as small volume to avoid freeze and thaw cycles
and was used within 3 months.
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Drug treatment
Single cell suspensions were counted and seeded in 12-well plates or 96-well
plates the day before drug treatment. On the day of treatment, cells were cultured to
approximately 50-70% confluence. Stock solutions of drugs were diluted in culture
medium to desired concentrations. Control solutions were prepared by diluting the
same volume of dissolving reagent used in drug stocks to culture medium. Culture
medium of cells was replaced by the medium containing drugs. Cells were cultured
for additional 72 hours.
Transfection of siRNA 
DharmaFECT  was  purchased  from  Thermo  Scientific.  The  transfection
procedure was done according to the product protocol.  In brief,  3000 cells  were
plated to each well of a 96-well plate and cultured in a 37°C overnight. On the next
day, 5 l of 2 M siRNA was mixed with 5l of plain DMEM medium in a 1.5-ml
eppendorf tube. In a separated tube, 0.5 l of DharmaFECT transfection reagent was
added to 49.5 l of plain DMEM. The mixtures were gently mixed by pipetting up
and down which were followed by 5 minutes of incubation at room temperature. The
diluted  siRNA was then added to the  diluted DharmaFECT transfection reagent,
mixed and incubated for another 20 minutes. When incubation was completed, 80 l
of  antibiotic-free complete  medium was added to the mixture for a  final  siRNA
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concentration of  100 nM. The medium from the  wells  of  the 96-well  plate  was
removed and replaced by the 100 l transfection mixtures. Transfection medium was
replaced with fresh culture medium 8-16 hours post transfection.  The cells  were
incubated at 37°C for additional 24 to 72 hours before harvest. Drug treatment could
start 24 hours after transfection.
MTT Assay
MTT  (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide)  was
purchased from USB Chemicals Corporation. The MTT powder was dissolved in
sterile  NP Water  to  a  final  concentration  of  5mg/ml  and  sterilized  by  passage
through a 0.22 m pore PVDF filter. Before treatments, 1x103 to 5x103 cells were
plated on a 96-well plate. When the treatment was completed, the cells were cultured
in a medium containing 1mg/ml of MTT for 3 hours. Following that, the medium
was discarded and 100ul of DMSO was added to each well in a 96-well plate. The
plate was shaken at a speed of 120 rpm for 15 minutes. Finally, absorbance was
measure at λ490 nm. For each treatment, the samples were repeated in triplicates.
Cell viability was calculated as ODtreatment/ODcontrol.
Luciferase reporter assays 
The  putative  miRNA binding  site  was  subcloned  in  the  pMIR-REPORT™
reporter (Invitogen) to detect endogenous miRNA expression. Before transfection,
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appropriate number of cells  was seeded in a 24-well  plate.  200 ng of the pMIR
reporter together with 1ng of the pRenilla reporter (Promega) were co-transfected
into the cells by lipofectamine 2000 (Invitrogen) according to standard protocols.
After  48  hours  of  incubation,  the  cells  were  harvested  for  measuring  luciferase
activity. Firstly, the cells were rinsed in ice-cold PBS twice and lysed in 1X Passive
Lysis Buffer (PLB) (Promega) for 15 minutes. Then the cells were scraped off and
transferred to a 1.5 ml microfuge tube. To clear the cell debris, the samples were
centrifuged in 13000 rpm at 4°C for 15 minutes. Then the activities of the firefly
luciferase  and  Renilla  luciferase  were  measured  by  using  the  Dual-Luciferase
Reporter Assay System (Promega).
Annexin V Assay
When  treatments  were  finished,  the  cells  and  the  culture  medium  were
collected as described above. Then 5 x 105 cells were re-suspended in 500 l of 1x
Annexin V binding buffer (Biovision). Thereafter, the cell suspension was incubated
with 5l of Annexin V-Cy5 antibody and 0.25 g of propidium iodide (PI) at room
temperature for 5 minutes in the dark. Finally, the samples were analyzed with BD
LSRFortessa Cell Analyzer. 
In vivo mouse model
Male nude mice at the age of 4-6 weeks old were provided by the Laboratory
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Animal  Services  Center  (LASEC)  of  the  Chinese  University  of  Hong  Kong
(CUHK). They were kept in pathogen-free, air-controlled conditions with 12-hour
light-dark cycles. Food and water supplied were sterilized.  All  experiments were
approved by the Animal Experimental Ethics Committee of the CUHK. 5 x 106 cells
re-suspended  in  100  µl  sterilized  PBS  containing  10%  matrigel  (BD)  were
subcutaneously injected into the left flank of nude mice to generate subcutaneous
(s.c.) xenografts. When tumors reached 5-10 mm in diameter, mice were randomly
allocated  into  different  groups  and drug treatment  got  started.  Stock solution  of
Brucein D dissolved in DMSO was diluted in sterilized PBS and administrated to
mice at the concentration of 1.5 mg/kg body weight through intraperitoneal (i.p.)
injections. Mice of control group received i.p. injections of the solvent only. Tumor
volumes and body weight were measured every 2 to 3 days. Tumor volumes were
calculated as length(mm)*width(mm)*height(mm)/2.
Tunel Assay (Terminal deoxynucleotide transferase dUTP Nick End Labeli
ng Assay) 
 Apo-BrdU-IHCTM was used for detecting apoptotic cells on Paraffin Embedded
Tissue. The subcutaneous tumor samples were harvested and fixed by methanol at
4°C for 24 hours. And then they were dehydrated and embedded in paraffin. Paraffin
blocks  were  sectioned  as  5  um  in  thick  onto  glass  slides.  Samples  were
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deparaffinized and rehydrated by immersing the slide in  following solutions  and
order: twice in xylene for 5 minutes, twice in 100% ethanol for 5 minutes, once in
90% ethanol for 3 minutes, once in 80% ethanol for 3 minutes, once in 70% ethanol
for 3 minutes and finally in 1X PBS for 1 minutes before drying the slide. Then, the
samples were digested with proteinase K at room temperature for 20 minutes for
permeabilization which was followed by inactivating the endogenous peroxidase as
described above. After this, the samples were equilibrated in 1X reaction buffer at
room temperature for 10 to 30 minutes. Sequentially, 1x complete labeling reaction
mixture was added to the sample and kept at  37°C for 1.5 hours.  Following the
incubation  with  blocking buffer,  the  samples  were  probed with  100  μl  antibody
solution.  Then  100  µl  of  DAB  solution  was  applied  to  the  samples  at  room




TRIzol® Reagent (Invitrogen) was used for RNA isolation. The samples, tissue
or cells, were firstly homogenized with Trizol and incubated at room temperature for
5  minutes.  For  1ml  of  Trizol  reagent,  200  l  of  chloroform was  added  to  the
homogenized samples,  which was followed by vigorous shaking for 15 seconds.
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After another 3 minutes of incubation, the samples were centrifuged at 12,000 × g
for 15 minutes at 4°C. Then, the top aqueous phase of the sample was transferred to
a new tube. 500 l of 100% propanol was added to the aqueous phase. The mixture
was then incubated at  room temperature for 10 minutes which was followed by
another centrifugation at 12,000 × g for 10 minutes at 4°C. The supernatant was
removed and 1 ml of RNase free 70% ethanol was added. After a brief vortexing, the
samples were centrifuged at 7500×g for 5 minutes at 4°C. The wash was discarded
and the RNA pellet was air dried. An appropriate amount of RNase free water was
used to  dissolve  the  RNA whose concentration  was subsequently determined by
NanoDrop (Thermo Scientific).
Synthesis of cDNA from miRNA
NCode™  miRNA  First-Strand  cDNA  Synthesis  Kit  was  purchased  from
Invitrogen  for  synthesizing  the  cDNA of  miRNA.  All  experimental  procedures
followed the protocol provided by the manufacturer. In brief, 2.5  g of RNA was
added to Poly(A) Tailing buffer (1xmiRNA Reaction Buffer, 25 mM MnCl2, 5 mM
ATP and Poly A Polymerase) supplied by the kit to a final volume of 25 l. After a
gentle mixing, the samples  were incubated at  37°C for 15 minutes.  Immediately
after the 37°C incubation, 4 l of the Polyadenylated RNA from previous step was
added to the annealing buffer. The mixture was incubated in the tube at 65ºC for 5
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minutes which was followed by a chilling on ice for 1 minute. Thereafter, 10 l of
2X First-Strand reaction mixture and 2  l  of SuperScript™ III RT/RNaseOUT™
enzyme mixture were added to the samples. The mixture was transfer to a thermal
cycler for a two-step incubation, 50 ºC for 50 minutes and then 85ºC for 5 minutes.
Finally, the samples were chilled on ice and stored at -20 ºC for qPCR analysis.
Synthesis of cDNA from RNA and quantitative PCR
The  synthesis  of  cDNA from  RNA used    High  Capacity  cDNA Reverse
Transcription Kit (Invitrogen). Firstly, 1 g of purified RNA was added to RT buffer
(1x RT buffer, 4mM dNTPs, 1x RT random primers, reverse transcriptase and RNase
inhibitor) as provided to the final volume of 25 l. After a gentle mixing and a short
spin down, the sample was placed in a thermal cycler with a program set according
to manufacturer’s guideline. 
The  relative  expression  level  of  genes  was  determined  by  using  semi
quantitative  PCR. 1  l  of  the  cDNA obtained from previous  step was added to
Power SYBR® Green PCR Master Mix (Invitrogen) containing corresponding set of
primers for gene detection. Then the samples were loaded in triplicated into a 96-
well or 384-well plate which was then placed in ABI 7900HT Fast Real Time PCR
for  measuring  the  CT  values.  The  relative  expression  level  of  each  gene  was




Cancer miRNA qPCR array plates were purchased from SBI. Reactions were
set up according to the protocol provided. For each sample assayed on one qPCR
plate, 500 ng total RNA was needed. cDNA of miRNA was synthesized using the
compatible  QuantiMir RT Kit. For each plate to be assayed by qRT-PCR, a master
mix  containing  SYBR Green,  universal  reverse  primer  and  miRNA cDNA was
prepared following instructions. For each well of a 96-well qPCR plate, 29 µl master
mix was loaded, to be mixed with 1 µl diluted primers from the primer plate. And
then the qRT-PCR plate could be applied for qRT-PCR analysis as described above.
Data was normalized to U6 control gene for further analysis.
DNA manipulation
Agarose gel electrophoresis and purification of DNA 
Several  types  of  agarose  gels  (typically  0.5%,  1.0%,  or  2.0%,  w/v)  were
prepared with TAE buffer containing 1X GelRed ™ staining solution (Biotium,Inc).
DNA samples were firstly mixed with loading buffer and loaded on the agarose gel
immersed in TAE buffer and separated at 150V for 25 minutes. The gel was placed
on a trans-illuminator emitting UV light to visualize the separated DNA. Then, the
gel  block  containing  desired  DNA  bands  was  excised  and  purified  with  the
QIAquick Gel Extraction Kit (Qiagen, Germany). The gel slice was weighed and an
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appropriate volume of buffer QG was mixed with the gel slice in a 1.5 ml microfuge
tube. The mixture was then incubated at 50°C until the gel was completely melted.
The mixture was then transfer to a mirco-column and centrifuged at 13,000 rpm in a
desktop  centrifuge  (Eppendorf,  Germany)  for  1  min.  The  flow  through  was
discarded. The resin retaining the DNA was washed with 750 μl of buffer PE and
centrifuged as above. The column-collection tube assembly was centrifuged for a
further 1 min to remove the residual PE buffer from the resin. The DNA was eluted
with 30 µl of NP Water and collected by centrifugation in a new clean microfuge
tube.
Restriction enzymes digestion 
All restriction enzymes and the respective 10x reaction buffers were obtained
from New England Biolabs, USA. Restriction enzyme digestion was mainly used in
DNA cloning. To digest DNA, 2 µg of plasmid DNA was mixed with 4 units of
restriction enzyme, 2 µl of 10x buffer, and the volume was brought to 20 µl with
Nano- water. Whenever more than two types of restriction enzymes were used, the
total  volume of the restriction enzymes added was kept  at  1/10 of total  reaction
volume. All the reactions were incubated in a 37°C incubator for 2 hours. 
Ligation of DNA fragments 
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The T4 DNA ligase (New England Biolabs, USA) was used for DNA ligation.
DNA insert and vector were mixed in approximately 3:1 molar ratio (total DNA was
not less than 100 ng). Then 2 μl of 10x buffer and 1 µl of T4 DNA ligase were added
to the DNA mixture. The reaction volume was brought to 20 µl with Nano-Pure
water and incubated at room temperature for 2 hours or at 16°C overnight. 
Polymerase chain reaction 
To prepare inserts for subcloning, template DNA (100 ng) was mixed with 2.5
µl of 10x PCR buffer, 0.5 µl of dNTP, 1 units of Taq polymerase(GoTaq® Flexi,
Promega) and 1 µg each of specific primers; then the volume was brought to 25 µl
by  Nano-Pure  water.  Thermal  cyclic  reactions  were  done  by  the  TaKaRa  PCR
Thermal Cycler Dice™ (Gradient Model) (TaKaRa, Japan). The reaction profile was
95°C for 5 min; 30 cycles of 95°C for 30 seconds, 58°C for 30 seconds (annealing
temperature varied for different primers), 72°C for 1 minutes (elongation time varied
depending on the size of DNA to be amplified), followed by 72°C for 7 minutes and
4°C for storage. When PCR was used to screen for positive transformants during
subcloning, overnight bacterial culture from single colony (1 µl) was used as the
template and the total reaction volume was 20 µl. 
Preparation of competent E. coli cells 
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A single colony of E. coli (strain of XL1-blue or DH5α) on an LB plate was
isolated and inoculated into 2 ml of LB medium which grown at 37°C for overnight.
The culture was then transferred into 100 ml of LB medium and grown until the
OD600 reached 0.3-0.5. The LB medium was then chilled on ice for 15 minutes. The
bacteria  were  pelleted  by centrifugation  and the  supernatant  was  discarded.  The
pellet was then resuspended with 30 ml of TFB1 solution and left on ice for 15 min.
The cell suspensions were centrifuged as above and subsequently resuspended with
4  ml  of  TFB2 solution.  After  another  15  minutes  incubation  on  ice,  the  TFB2-
resuspended bacteria were transferred into pre-chilled 1.5-ml microcentrifuge tubes
as 200 µl aliquots and stored at -80°C. 
Transformation of E. coli cells 
Either 1ng of plasmid DNA or all of the ligation mixture was mixed with 100
µl of competent E. coli cells and left on ice for 10 minutes. The cells were heat
shocked in a 42°C water bath for 90 seconds which is following by chilling on ice
for 90 seconds. The transformation mix was then mixed with 250 µl of LB medium
and shaken in a 37°C environmental shaker for 30 minutes. The cells were pelleted
at 3,000 rpm in a desktop centrifuge for 1 minute. Finally, 100 µl of the bacteria
culture  was  spread on a  LB plate  containing  appropriate  antibiotics,  and grown
overnight in a 37°C incubator. 
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Small scale plasmid isolation from E. coli (mini-prep) 
QIAprep  Spin  Miniprep  Kit  (Qiagen,  Germany)  was  used  for  small  scale
plasmid isolation. A single colony of E. coli (XL1-blue or DH5α) was inoculated
into 5 ml of LB medium containing appropriate antibiotics at 37°C for overnight.
The bacteria were pelleted and resuspended in 250 µl S1 buffer. To lyse the bacteria,
250 µl of S2 buffer was added and the mixture was incubated at room temperature
for 5 min. To neutralize the lysate and precipitate cellular proteins, chilled S3 buffer
(100  µl)  was  added  and  the  lysate  was  incubated  on  ice  for  15  minutes.  The
supernatant was pipetted to QIAprep spin column and centrifuged at 13,000 rpm for
30 seconds.  After  discarding the flow-through,  750 of  buffer  PE was applied to
column  which  was  spun  again  as  above.  After  removing  the  flow-through,  the
column was centrifuged for another minute to  remove residual wash buffer.  The




Brucein D inhibited the growth of HCC cells both in vitro and in vivo
Considering  BD’s  cytotoxic  effect  on  pancreatic  cancer  cell  lines  as
previously reported, we firstly investigated BD’s effect on HCC cell growth by
MTT assays. There were 5 HCC cell lines being tested. They are PLC, HepG2,
Hep3B, Huh7, and Bel7404. The cell line MIHA is a normal human hepatocyte
cell line, which serves as a normal control. MTT results (figure 1) revealed that
BD  suppressed  cell  proliferation  in  all  the  5  human  HCC  cell  lines  in  a
concentration-dependent manner. However, the growth inhibitory effect of BD
didn’t markedly affect MIHA. By calculating the IC50 values (table 1), we also
found that IC50 of MIHA was significantly higher than that of cancer cells,




Figure 1: Brucein D inhibited HCC cell growth in vitro.
Cells were treated with BD at gradient concentrations ranging from 0.25 to 1.5
µM for 72 hours. MTT assays were applied to evaluate cell proliferation. For each
cell  line,  cell  viability  was  normalized  to  the  correspondent  untreated  control
sample. BD suppressed the growth of HCC cell lines in a concentration-dependent
manner, but did not significantly affect the growth of MIHA.
Table 1. IC50 values of BD on human normal hepatocyte cell line MIHA and 5
human HCC cell lines.
IC50  values  were  calculated  by  GraphPad  Prism  software  based  on  MTT
results as previously shown. IC50 of MIHA is much higher than that of cancer cells.
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We further evaluated BD’s anti-liver cancer effect in vivo (figure 2). HCC cells
were subcutaneously inoculated in nude mice. When the tumors reached 5mm in
diameter, mice were given BD treatment or solvent alone through i.p. injections.
Tumors in the control group grew exponentially. Conversely, BD suppressed tumor
growth to a relatively low level. Similar effect could be observed in both Hep3B
(figure 2A) and Bel7404 (figure 2B) cell lines. These results provided evidence that
BD inhibited HCC cell growth in vivo as well. Additionally, it was desirable to find
that  BD treatment  did  not  result  in  remarkable  body weight  loss  on  nude  mice
(figure 2C). No other drug-induced side-effect was found either. It suggested that
BD treatment did not have profound toxicity to the mice bearing tumors.
To sum up, BD exerted anti-cancer effect on HCC both in vitro and in vivo.
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Figure 2.
Figure 2: Brucein D inhibits HCC cell growth in vivo.
(A and B): BD inhibited the growth of HCC s.c. tumors in nude mice. Hep3B
(A) and Bel7404 (B) cells  were subcutaneously inoculated into nude mice. Mice
were treated with either 1.5mg/kg body weight BD or control solution through i.p.
injections. Schedules of treatment were every Monday, Wednesday and Friday for 3
weeks (A) or daily for 10 continuous days (B). Tumor volumes between groups were
considered as significantly different when p < 0.05. (*, p < 0.05, n = 11 (A), n = 4
(B).) 
(C): No significant body weight loss was caused by BD. Mice bearing Hep3B
s.c. tumors were treated with BD at the dosage of 1.5 mg/kg body weight or control
solution every Monday, Wednesday and Friday for 3 weeks.
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BD induced apoptosis in HCC cells
The  next  step,  we  attempted  to  find  out  how  BD  suppressed  cell  growth.
Previous study proposed that BD induced apoptosis in pancreatic cancer cell lines
(Lau, 2009; Lau, 2010). Hence we examined whether BD had similar function for
HCC cells. We conducted annexin V assays for 3 different HCC cell lines. Through
flow cytometric analysis (figure 3), we found that there was a significant increase of
apoptotic cells  after BD treatment as compared to control samples. These results
showed that BD induced apoptosis in HCC cells and implied that apoptosis probably
played an important role in BD-induced growth inhibition.
Moreover,  we confirmed the  apoptotic  activity of  BD with  in  vivo  studies.
Hep3B tumor sections from the previous animal study were applied to TUNEL assay
to  detect  apoptosis.  TUNEL positively  stained  cells  represent  cells  undergoing
apoptosis. From IHC analysis (figure 4), we could find that, in the aspects of density
and distribution, there were remarkably more positive-stained cells in BD treated
samples than in control samples. The result was consistent with in vitro findings,
showing that BD induced apoptosis to suppress cell growth both in vitro and in vivo.
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Figure 3.
Figure 3: BD induced apoptosis in vitro.
HCC cell lines, PLC, HepG2 and Hep3B, were applied to annexin V and PI
double staining after 72 hours treatment of 0.7 μM BD or control reagent. Flow
cytometric analysis was carried out to detect apoptotic cells. Q1 (Annexin V + / PI -)
= early apoptotic cells; Q2 (Annexin V + / PI +) = late apoptotic cells; Q3 (Annexin
V - / PI -) = live cells; Q4 (Annexin V - / PI +) = dead cells (e.g. necrotic cells). A
statistical analysis of the percentage of apoptotic cells (Q1+Q2) / (Q1+Q2+Q3+Q4)
is shown. It revealed that BD induced apoptosis in different HCC cell lines.
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Figure 4.
Figure 4: BD induced apoptosis in vivo.
Sections of Hep3B s.c. tumors samples from mice treated with BD or control
reagent  were  applied  to  TUNEL-IHC  assay.  Representative  images  are  shown.
Arrows  point  at  dark  dots  that  are  TUNEL positive-stained  cells.  Quantitative
analysis  of  IHC  data  are  presented  below.  Percentage  of  apoptotic  cells  were
calculated as number of TUNEL-positive cancer cells / number of total cancer cells
in each field at 200X magnification. More HCC cells underwent apoptosis after BD
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treatment (P = 0.01, n = 5).
miR-95 is an target of BD to modulate cell growth
In order to investigate the mechanisms of BD-induced growth inhibition, we
tried to find BD’s downstream effectors. There is growing evidence suggesting that
aberrant  expression  of  miRNAs  is  associated  with  cancer  pathogenesis.  We  are
particularly  interested  in  whether  miRNAs  are  involved  in  the  process  of  BD-
induced cell apoptosis. To answer this question, we performed a qPCR miRNA array
profiling. Figure 5 illustrates the procedure of the screening. Briefly, HCC cell line
PLC was treated with either 0.7 μM BD or control reagent. Total RNA was extracted
and cDNA of miRNAs was synthesized for both samples. They were then applied to
the qPCR screening. This array contains primers of 95 mature human miRNAs that
have published implications  in cancer.  U6 primer is  also included as an internal
control. The data analyzed by quantitative real-time PCR referred to the abundance
of each miRNA in the sample tested, that was normalized to U6 control gene. By
comparing the abundance of the miRNAs between the BD treated sample and the
control  sample,  we  may  know  the  miRNAs  that  were  up-regulated  or  down-
regulated by BD. 
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Figure 5.
Figure 5: Flow chart of miRNA screening for BD downstream targets.
PLC cells were treated with either 0.7 μM BD or control reagent. Total RNA
was extracted and cDNA of miRNAs was synthesized for both samples. Then they
were applied to the qPCR analysis. This array contains primers of 95 human cancer
miRNAs that have published implications in cancer.  U6 primer is  as an internal
control. The data analyzed by quantitative real-time PCR referred to the abundance
of individual miRNA normalized to U6 control gene. By comparing the abundance
of the miRNAs between the BD treated sample and the control sample, we found a
panel of miRNAs was significantly changed after BD treatment (fold change greater
than 1.5 folds.)
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A brief summary of the result of our primary screening is shown in table 2.
Changed  expression  pattern  of  miRNAs were  seen  after  BD treatment.  Relative
expression level of miRNAs spanned from 0.19 to 6.19. The fold of change was
regarded as significant if it is greater than 1.5. Expression levels of 39 miRNAs were
significantly changed after BD treatment. Among them, 25 were down-regulated and
14 were up-regulated. They were all considered as potential targets of BD. 
To validate the candidate miRNAs, we individually examined the expression
levels of the miRNAs from the initial screen. As figure 6 shows, miR-95, miR-153,
miR-154, miR-183, miR-186, miR-196a and miR-488 were confirmed to be true
positive targets. Expression of miR-95, miR-153, miR-183, miR-186 and miR-196a
were decreased, whereas expression of miR-154 and miR-488 were increased. They
may  play  a  role,  at  least  to  some  extents,  in  BD-modulated  growth  inhibition.
Accession numbers and sequences of the 7 validated miRNAs are listed in table 3.
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Figure 6: Validation of miRNAs as true positive targets of BD.
BD decreased expressions of miR-95, miR-153, miR-183, miR-186 and miR-
196a, whereas increased expressions of miR-154 and miR-488. 
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Table 3. Accession number and mature sequence of the target miRNAs
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To further identify which miRNA was a direct effector of BD, we carried out
functional  validation  experiments.  At  this  stage,  our  hypothesis  was  that  if  BD
suppresses the expression of a miRNA to inhibit cell growth, overexpression of this
miRNA  would  impair  BD’s  inhibitory  effect  on  cell  growth.  To  justify  this
hypothesis,  we firstly selected miR-95 for  functional  validation.  As MTT results
demonstrated (figure 7), replenishing miR-95 expression by transfection of miRNA
mimic rendered HCC cells more resistant to BD treatment, as compared to negative
control  (NC).  This  growth  advantage  provided  by  miR-95  can  be  observed  in
different HCC cell lines, including PLC (figure 7A), HepG2 (figure 7B) and Hep3B
(figure  7C).  This  finding  supported  our  hypothesis  that  restoration  of  miR-95
expression can rescue the suppression of HCC cell growth caused by BD. However,
other miRNAs that we screened, such as miR-153, failed to display similar function
in neither PLC (figure 8A) nor Bel7404 (figure 8B) cells.
From these results, we believed that miR-95 was a downstream effector of BD
and we proposed that BD repressed miR-95 to inhibit HCC cell growth.
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 Figure 7.
Figure 7: Overexpression of miR-95 increased resistance of HCC cells to BD.
PLC (A), HepG2 (B) and Hep3B (C) cells were transfected with either miR-95
mimic or negative control (NC) RNA. 24 hours after transfection, cells were given
0.7 µM BD treatment or control reagent for 72 hours. MTT assays were applied to
measure cell  growth. Cell  growth rate was normalized to  control reagent  treated




Figure 8: miR-153 mimic had no effect on sensitivity of HCC cells to BD.
PLC (A) and Bel7404 (B) cells were transfected with either miR-153 mimic or
negative control (NC) RNA. 24 hours after transfection, cells were given 0.7 µM
BD treatment or control reagent for 72 hours. MTT assays were applied to measure
cell  growth.  Cell  growth  rate  was  normalized  to  control  reagent  treated  cells.
Transfection of miR-153 mimic failed to significantly affect cells’ sensitivity to BD.
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Identification of CUGBP2 as a downstream target of miR-95
Now that BD suppressed miR-95 to inhibit cell growth, the next question was
how miR-95 executed its function in HCC. Firstly we wanted to find downstream
target genes of miR-95. We searched databases, for instance, Target Scan and Pic
Tar, to predict target genes whose 3’UTR potentially interact with miR-95. mRNAs
of 6 genes (CUGBP2, SHOX2, GNAI2, SELS, NR4A2, and OAZ2) were shown as
potential targets. Then we tested whether the expression of these candidate genes
were correlated with the abundance of miR-95 by qPCR analysis. As a target mRNA
of miR-95, it was expected that its expression would be repressed after transfection
of miR-95 mimic and on the contrary would increase after transfection of miR-95
inhibitor. Among the 6 genes, only CUGBP2 fitted this model. The other 5 genes did
not  exhibit  similar expression pattern (figure 9A).  Moreover,  we examined BD’s
effect  on  CUGBP2  expression.  We  observed  an  induction  of  CUGBP2  gene
expression after BD treatment (figure 9B) where miR-95 expression was suppressed
as previous shown (figure 6A). These results further proved that CUGBP2 was a




Figure 9: CUGBP2 was a downstream target of miR-95.
(A)Relative gene  expression  levels  of  6  predicted  targets  of  miR-95.  mRNA
levels of the genes were accessed by qPCR analysis in PLC cells, 48 hours
post  transfection  of  miR-95  mimic  /  negative  control  (NC)  or  miR-95
inhibitor / NC inhibitor. Only expression pattern of CUGBP2 matched with
our expectation.
(B) CUGBP2 expression was increased after 0.7 µM BD treatment for 72 hours
in  PLC  cells.  Relative  mRNA expression  level  was  measured  by  qPCR
analysis.
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At last, we went on to investigate if miR-95 inhibited CUGBP2 mRNA through
direct binding. Thus, we performed luciferase reporter assays to determine whether
the predicted seed sequence on 3’UTR of CUGBP2 mRNA was a functional target
site for miR-95. As illustrated in figure 10A, we constructed two reporter plasmids.
Both of them had a 350 bp 3’UTR sequence of CUGBP2 mRNA. The wild-type
(WT)  plasmid  contained  the  putative  miR-95  seed  region  whereas  the  mutant
plasmid had this region deleted. Complementary binding of miR-95 to the reporter
plasmid would suppress the luciferase signals. Luciferase reporter assays revealed
that  miR-95  suppressed  luciferase  signals  of  WT  plasmids,  but  did  not  affect
luciferase  signals  of  mutant  plasmids.  It  indicated  that  miR-95  functionally
interacted with 3’UTR of CUGBP2 mRNA but not the mutant one. Therefore, based
on the above results, CUGBP2 was identified as a direct downstream target of miR-
95.
CUGBP2 is an RNA binding protein. Some research reported that it induced
apoptosis  in  breast  cancer  and  colon  cancer  (Mukhopadhyay,  2003;  Natarajan,
2008). Given the pro-apoptotic nature of CUGBP2, our proposed the mechanism of
BD-modulated cell growth in HCC could be that BD repressed the expression of
oncogenic  miR-95  and  subsequently  resulted  in  restoring  the  pro-apoptotic
downstream target CUGBP2 to induce apoptosis, so as to inhibit cell growth.
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Figure 10.
Figure 10: miR-95 directly bound to the seed sequence in 3’UTR of CUGBP2
(A)Structures  of  wild-type  (WT)  and  mutant  luciferase  reporter  plasmids.
Details are described in the text.
(B) Compared  to  NC,  miR-95  mimic  suppressed  luciferase  signals  in  WT
plasmids, which contained seed region in 3’UTR of CUGBP2, but not in
mutant  plasmids.  Luciferase  report  assays  were  conducted  in  human
embryonic  kidney  293T  cells  48  hours  after  co-transfection  of  reporter
plasmids and miR-95 mimic / negative control (NC) RNA.
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4. Discussion
With  a  yearly  growing  incidence  rate  worldwide,  primary  liver  cancer,
dominantly hepatocellular  carcinoma  (HCC),  remains  a  difficult  task  in  medical
care.  Considering  its  poor  response  to  surgical  resection,  chemotherapy,  and
embolization, seeking novel and effective therapeutic methods for HCC is crucial.
Brucein D (BD), a quassinoid isolated from Brucea javanica fruit, has been reported
to exert cytotoxic effect in pancreatic cancer cell lines  (Lau, 2009). It shows great
potential  of BD to be a novel therapeutic agent for cancer.  However,  BD’s anti-
cancer effect on other types of cancer still needs extensive exploration. In this study,
we confirmed that BD possessed anti-liver cancer activity both in vitro and in vivo
and also disclosed some underlying mechanisms of this action.
Through cell line and animal experiments, we reported for the first time that
BD exhibited desirable anti-cancer effect on HCC cells. It effectively inhibited HCC
cells  proliferation  in  vitro  but  did  not  markedly  suppress  the  growth of  normal
hepatocyte cell line. In a mouse model, it was able to repress the growth of HCC
tumors without resulting in remarkable body weight loss. We also found that BD
induced  apoptosis  in  HCC  cells  both  in  vitro  and  in  vivo,  which  could  be  an
important way for BD to cause cell death. All these findings were consistent with
previous publication about BD’s effect on pancreatic cancer cells  (Lau, 2009), and
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further demonstrated therapeutic potential of BD to treat liver cancer.
However, how a naturally occurring compound can inhibit the growth of cancer
cells remains largely unknown. With the purpose to decode the mechansims, we got
started from the aspect of miRNA regulation, because more and more evidence has
pointed  out  that  deregulation  of  miRNAs  plays  an  important  role  in  cancer
pathogenesis.  We performed  a  cancer  miRNA screening  to  search  miRNAs  that
would be affected by BD. From primary screening, we did find an altered expression
profile of miRNAs induced by BD in HCC cells. After BD treatment, 25 miRNAs
were down-regulated and 14 were up-regulated. Seven of them were proved to be
true positive. Among those down-regulated miRNAs, we found that overexpression
of  miR-95  could  increase  cells’  resistance  to  BD  treatment.  Furthermore,  we
identified a pro-apoptotic gene CUGBP2 as a direct target of miR-95. These results
suggested that miR-95 and CUGBP2 could be downstream effectors of BD, and we
proposed one of the possible mechanisms of BD’s anti-liver cancer activity was, at
least  in  part,  through  inhibiting  oncogenic  miR-95  which  degrades  tumor
suppressive  CUGBP2,  and  thereby  inducing  apoptosis  in  HCC  cells.  Other
mechanisms  by  which  BD  causes  growth  inhibition  require  further  studies,
especially those without involvement of miRNAs.
The finding of miR-95 as a target of BD is novel. miR-95 has been reported to
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act  as  an oncogenic miRNA in pancreatic  cancer,  colorectal  cancer  and cervical
cancer  (Zhang,  2009;  Huang,  2011;  Cheng,  2005).  But  few  studies  have  been
conducted on miR-95’s function in liver cancer till now. In our study, it acted like an
oncogene, which was in accord with the published data regarding other cancer types.
Thus far, there has been little research focusing on miRNA targets of a drug. We
observed  expression  of  a  panel  of  miRNAs  was  changed  after  BD  treatment.
Interestingly, only miR-95 could reverse the inhibitory effect of BD on HCC cells,
implying possibly miR-95 was a specific miRNA target of BD.
However,  several  questions  still  remained  unanswered  in  this  study.  For
example,  how  does  BD  regulate  miR-95?  If  BD  directly  targets  miR-95,  the
chemical structure of BD would be a crucial factor for its interaction with miR-95,
which  requires  in-depth  study.  We  would  also  like  to  know  in  which  step  BD
suppresses  miR-95,  for  instance,  the  generation  of  pri-miR-95 or  pre-miR-95.  If
miR-95 is  not a direct target of BD, an extensive investigation for the upstream
regulators of miR-95 is needed. In addition, whether miR-95 is a specific target of
BD has not yet been confirmed. At least we found in this study that expression of a
panel of miRNAs was noticeably influenced by BD. If other molecules mediate BD-
induced growth inhibition via miR-95, the story may be even more complex.
With  regard  to  the  identification  of  downstream  targets  for  miR-95,  we
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suggested  CUGBP2  as  an  effector  in  this  setting.  From  published  literature,
CUGBP2 functions as a tumor suppressor gene, inducing apoptosis in breast cancer
and colon cancer (Mukhopadhyay, 2003; Natarajan, 2008). This is in agreement with
our  scenario  that  oncogenic  miR-95  inhibits  expression  of  tumor  suppressive
CUGBP2. But in this study, we only showed BD can up-regulate the pro-apoptotic
CUGBP2. We still lack sufficient evidence to prove that increased CUGBP2 level is
a direct cause for BD-induced apoptosis. Future works could be done to examine
whether silencing CUGBP2 can impair BD’s impact on cell death. Moreover, the
method we used to screen downstream targets for a miRNA is not comprehensive
enough. miRNA-mediated gene silencing could be carried out by either cleavage of
mRNA or inhibition of protein synthesis.  We just  focused on those target  genes
being  degraded  at  post-transcriptional  level  because  we  merely  relied  on  qPCR
analysis to determine which mRNA expression matched with the expected pattern of
change.  This  method  actually  resulted  in  precluding  the  real  targets  that  were
inhibited  at  protein  synthesis  level  without  changes  of  mRNA abundance.  For
detection  of  target  genes  that  are  silenced  at  translational  level,  proteomics
approaches should be applied, for example, two-dimensional gel electrophoresis and
mass spectrometric analysis. Nevertheless, the identification of CUGBP2 as a direct
target of miR-95 has been confirmed in this study through functional assays. 
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In regards with the therapeutic potential of BD in cancer, it is exciting to know
that BD inhibits not only pancreatic cancer cells but also HCC cells growth in pre-
clinical  studies.  We  expect  that  targeted  therapy  aiming  at  miR-95  or  restoring
CUGBP2  would  sensitize  patients’ response  to  BD.  Admittedly  this  study  was
largely based on in vitro manipulation and relatively lacked sufficient  functional
experiments.  Although  future  investigation  is  needed,  current  results  offer  new
insights into cancer research and development of novel therapeutic approaches. In
summary, a putative pathway of BD’s anti-cancer effect in HCC cells is confirmed,
which might be one step further in understanding BD’s mechanism in curing liver
cancer. 
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Part II: Genome-wide RNAi screening identifies tumor metastasis





Ranking  the  fourth  leading  cause  of  cancer  death  in  western  countries,
pancreatic cancer has extremely poor prognosis, with an overall 5-year survival rate
of as low as 1 to 4 %  (Jemal,  2007).  Despite that great efforts have been made
during  the  past  decades,  improvement  for  the  outcome of  this  fatal  disease  still
challenges medical world. Lack of conspicuous symptoms and efficacy screening
biomarkers prevent patients with pancreatic cancer from being detected in the early
stage. Due to the delayed diagnosis, pancreatic cancer often presents in advanced
stages. 
Currently,  the  only potentially  radical  treatment  for  pancreatic  cancer  is  by
surgical resection together with adjuvant chemotherapy, which could raise the 5-year
survival  rate  to  15-20%  (Ahrendt,  2002;  Neoptolemos,  2004).  But  only a  small
group of patients are sustainable to accept curative therapy. The majority of patients
64
is  unresectable  at  the  time  of  presentation  and  thus  requires  palliative  therapy
(Andersson, 2004). The mean survival time for these patients is merely 4 months
(Jemal,  2004).  It  should be noted that  a  number of patients  undergoing curative
operation finally develop recurrence and eventually should be given palliative care.
As  a  prevalent  palliative  treatment,  chemotherapy  with  gemcitabine  is  able  to
prolong life  span to  approximately 6 to  7 months  and improve life  quality to  a
certain  extent  (Burris,  1997;  Ishii,  2005).  However,  the  effect  of  chemotherapy,
sometimes in combination with radiotherapy, seems far from satisfactory. Although
gemcitabine serves as a first line agent for pancreatic cancer, it only gets a modest
response in pancreatic cancer  patients.  Additionally,  rapid emerging resistance to
chemotherapy remains a difficult-to-tackle problem. Moreover, due to the invasive
nature  of  pancreatic  cancer,  almost  100%  pancreatic  cancer  patients  develop
metastasis and die  (Li, 2004). The presence of metastasis implies poor response to
all  conventional treatment,  including surgery,  chemotherapy, or radiation therapy,
further complicates treatment for the disease.
All these features render pancreatic cancer hopeless.  We are in great need of a
deeper  and  clearer  understanding  of  the  biological  characteristics  of  pancreatic
cancer.  The  investigation  of  novel  therapeutic  methods,  for  instance,  targeted
therapy or molecular therapy, is expected to bring in new light to this disease. 
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Pancreatic ductal adenocarcinoma (PDAC)
Pancreatic  ductal  adenocarcinoma  is  the  most  common  type  of  pancreatic
cancer. Histological analysis reveals a resemblance of this kind of tumor to the duct
cells  of pancreas.  It  contributes  to  more than 85% of  pancreatic  neoplasms.  For
simple, it may also be regarded as pancreatic adenocarcinoma or pancreatic cancer. 
Human pancreas also sustains other types of tumors which derive from different
pancreatic  cells.  Different  origin  gives  rise  to  varied  biological  behaviours.
Examples  include  acinar-cell  carcinoma  which  grows  as  zymogen  granules,
pancreatic endocrine tumor which produces hormone along with tumor growth, and
serious cystadenoma which is featured by cystic growth. All these three types are
rare events in diagnosis a pancreatic cancer.
Molecular basis of PDAC
The  understanding  of  crucial  gene  mutations  in  PDAC is  deemed  valuable
approach to address clinical problems. It has been shown that development of PDAC
is  associated  with  mutations  of  KRAS,  CDKN2A,  TP53,  BRCA2  and
SMAD4/DPC4 (Bardeesy, 2002).
KRAS
Approximately 100% of pancreatic adenocarcinoma cases bear KRAS mutation
and the frequency of KRAS mutation positively correlated with disease progression
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(Rozenblum, 1997). Following activation of KRAS mutation, p21 activity is induced
possibly through the mitogen-activated protein kinase (MAPK) pathway  (Biankin,
2001). It is well established that activation of RAS family mutations gives rise to a
series  of  cellular  responses,  such  as  increased  proliferation,  invasion,  and  cell
survival through several downstream pathways  (Shields, 2000). But the targets of
KRAS mutation in PDAC progression remain elusive. It has been pointed out that
autocrine epidermal growth factor (EGF) promotes pancreatic cancer tomorigenesis
by triggering the phosphatidylinositol 3-kinase (PI3K) pathway (Korc, 1992; Sibilia,
2000). EGF-family ligands (for example TGF-alpha and EGF) and receptors (for
example EGFR and ERBB2) consistently overexpressed in PDAC (Friess, 1996). 
TP53
Mutation  of  tumor  suppressive  TP53  probably  contributes  to  the  genetic
instability  of  PDAC  for  the  tumor  has  intratumoral  heterogeneity and genomic
rearrangements  (Gorunova, 1998). Inactivation of DNA-damage response which is
dependent on p53 facilitates cell survival with short telomeres (Chin, 1999). Studies
on a large number of human PDAC cell lines suggested that loss of telomeres from
chromosome ends was often observed, supporting the notion that pancreatic cancer
genetic instability is relevant to short telomeres and telomere malfunction initiates
pancreatic carcinogenesis (Gisselsson, 2001). 
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CDKN2A
Disturbed  function  of  CDKN2A  by  mutation,  deletion  or  promoter
hypermethylation is found in 80% -95% PDAC  (Rozenblum, 1997). The locus of
this tumor suppressor gene (TSG) also encodes another two TSGs, INK4A and ARF.
Therefore, many cases of pancreatic cancer with CDKN2A mutation also sustain
loss of  INK4A and ARF functions,  thus  impairing retinoblastoma (RB) and p53
pathways  (Sherr,  2001).  How these genetic  bases are  translated into complicated
clinical  aspects  and  subsequently  guide  future  work  on  pancreatic  cancer  still
requires active investigation.
Gemcitabine treatment in PDAC
Gemcitabine is  currently a gold-standard chemotherapeutic  agent for locally
advanced and metastatic pancreatic cancer. It releases cancer-related pain, prevents
body weight loss, improve life quality, and thus increase survival rate  (Andersson,
2009).
Gemcitabine  is  a  nucleoside  analogue.  It  exhibits  its  cytotoxic  activity  by
incorporation into DNA or RNA so as to mask chain termination (Huang, 1991; Ruiz
van  Haperen,  1993).  Upon  introduction  into  patients,  the  uptake  of  the  drug  is
facilitated  by  nucleoside  transporters,  mainly  by  human  equilibrative  nucleoside
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transporter-1 (hENT-1) and by human concentrative nucleoside transporter (hCNT)
as  well  (Garcia-Manteiga,  2003).  Following  intracellular  uptake,  gemcitabine  is
phosphorylated  by  a  series  of  kinases  into  difluorodeoxycytidine  triphosphate
(dFdCTP), which serves as a substrate of DNA and RNA polymerase, to exert its
cytotoxic effect  (Ruiz van Haperen,  1994).  A series of  actions participate  in  the
processes  of  gemcitabine’s  uptake  and  metabolism  before  it  functions  as  a
chemotherapeutic drug.
However, gemcitabine generates only 5.4% partial response rate (Burris, 1997;
Ishii,  2005), even though it proves to be a first line chemotherapy for pancreatic
cancer. For many cases, patients respond well to gemcitabine at the very beginning
and then suffer  from resistance  rapidly.  It  is  suggested  that  the  chemoresistance
could be either intrinsic or acquired along with drug treatment. It has been proposed
that there might be a subset of cells possessing resistant feature preexisting in the
tumor.  Alternatively,  rapidly  developed  resistance  derives  from  tumor  stromal
interactions (Kim, 2008).
Great  efforts  have  been  put  to  uncover  the  mechanisms  of  gemcitabine
chemoresistance for years. Some explanations have been proposed, which mainly
focused on gemcitabine  metabolism.  Decreased expression of  hENT1 leading to
reduced intracellular uptake of gemcitabine is one of the established mechanisms
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(Mackey,  1998).  Some  clinical  studies  also  confirmed  the  correlation  between
hENT1  expression  level  and  gemcitabine  treatment  effect  (Spratlin,  2004;
Giovannetti,  2006). In addition to drug uptake, defect in drug phosphorylation is
another aspect associated with gemcitabine resistance. It has been reported that low
activity of MT (dCK), which mediates gemcitabine phosphorylation, is relevant to
both  intrinsic  or  acquired  gemcitabine  resistance  (Kroep,  2002).  Another  study
implied  that  overexpressed  HMGA1  protein  complex,  which  consists  of
transcription factors and locates downstream of RAS signaling pathway, contributes
to increased gemcitabine resistance (Liau, 2008).
Metastasis
Overview
Metastasis is the spread of cancer cells from a location of origin to a secondary
site,  followed by the growth of tumor in the new environment. The emerging of
metastasis, which contributes to more than 90% cancer mortality  (Hanahan, 2011;
Fidler, 2003), endows cancer to be the most deadly disease. Since Stephen Paget’s
‘seed  and  soil’ theory a  century before,  metastasis  has  been  drawing  increasing
attention  from  scientists.  The  mechanism  of  metastasis,  however,  still  remains
mysterious. Owing to recent technological advances, we have gained some insights
into the complexity of metastasis: the understanding of the stepwise nature of the
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process (Chambers, 2002; Sahai, 2007), the interactions between the tumor and the
surrounding  stroma(Joyce,  2009);  the  regulation  of  sets  of  genes  and  signaling
pathways  that  determines  cancer  cells  to  metastasize  or  not  (Fidler,  2003);  the
factors that drive organ specific metastasis; the evolutionary relationship between
primary tumor and metastatic lesions (Hynes, 2003); But the systemic, cellular, and
molecular bases of this process are far from elucidated, rendering cancers difficult to
treat. A better understanding of the profound mechanism of metastasis will bring in
benefits to cancer management, and cancer prevention as well. 
The stepwise process of metastasis
A series  of  sequential  steps  give  rise  to  metastasis.  At  the  very beginning,
primary tumor grows dependent on nutrients diffusion. Those aggressively growing
tumors secrete angiogenic factors to stimulate the formation of a capillary network
around  them.  This  vascular  network  in  turn  nourishes  the  tumor.  Following  the
continuous proliferation of primary tumor, the cascade of metastasis is triggered by
the accumulative genetic changes and activated signaling pathways. 
Some cancer cells acquire the ability to detach from the tumor mass and to
invade  the  surrounding  stroma.  This  process  is  characterized  as  epithelial-to-
mesenchymal transition (EMT), which probably serves as the most actively explored
feature of metastasis. EMT is the first but critical step in the long journey of a cancer
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cell  to  colonize  a  new  location.  Epithelial  cancer  cells  obtain  features  of
mesenchymal  cells,  leading to  a  reduced cell–cell  adhesion and apical-basal  cell
polarity,  as  well  as  induced cell  motility.  In  morphological  aspect,  cells  become
spindle-like, which resembles fibroblast cells. On the molecular level, the expression
of epithelial-associated markers such as E-cadherin, ZO-1, and beta-catenin reduces
and on the contrary the expression of mesenchymal markers such as fibronectin, N-
cadherin, and vimentin increases.  
The thin-wall vessels failing to resist the penetrating of invasive tumor cells
allow the entry of cancer cell into circulation. Both vascular and lymphatic systems
will  suffer.  However,  most  of  the  circulating  cancer  cells  will  die  in  the  blood
stream. The remaining survival cells get trapped when they travel to the capillary
beds of distant organs. By the similar mechanism of their entry into blood vessels,
cancer cells anchored the vessel wall and exit the circulation. The above processes
are named intravasation and extravasation in metastasis studies.
Upon their arrival in a new location, adapted growth of cancer cell in the new
microenvironment  marks  the  success  of  metastasis.  It  is  still  not  an  easy  task,
requiring  the  interplay  between  the  supportive  target  tissues  and  the  wandering
tumor cells.
Complicated as it is, the process of metastasis is precisely orchestrated by a
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network of multiple genes and signaling pathway. Failure in anyone of these steps
will  be rate-limiting.  In addition,  the coordination between metastasis  promotion
factors and suppression factors  determines  whether  metastasis  to proceed or not.
Cancer  cells  must  overcome  all  the  suppressive  barriers  and  make  use  of  the
promotion advantages to get metastatic.
Despite considerable advances in unraveling this complexity process in recent
years, the exact mechanisms of metastasis in molecular and cellular levels are still
largely  unknown.  Many  widely  accepted  points  of  view  are  undergoing
reconsideration.  Tackling problems related to cancer metastasis continues to be a
challenging issue. Investigations into this field have a great importance for cancer
research and hopefully will guide us to more efficient management of cancers.
 
Metastasis of pancreatic cancer
Pancreatic cancer cells may spread by direct extension from the pancreas to
adjacent structures. They may also spread to regional lymph nodes. Most common
sites  of  distant  metastatic  spread  include  the  liver  and  the  lungs  (via  the
bloodstream)  and  the  peritoneum (abdominal  cavity).  However,  tumor  cells  can
metastasize to other parts of the body as well. 
SOX9
SOX9 (sex determining region Y-box 9) is a member of the sex-determining
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region Y-box (SOX) family which  belongs  to  a  superfamily of  the  transcription
factors  containing  a  high  mobility  group  (HMG)  box.  SOX  proteins  regulate
transcription by binding to the DNA sequence (A/T)(A/T)CAA(A/T)G through their
HMG domain (Kamachi, 2000). 
SOX9  is  required  for  many  important  developmental  processes  including
neurogenesis  (Stolt, 2003), chondrocyte differentiation  (Akiyama, 2002), male sex
determination (Chaboissier, 2004), respiratory system development (Houston, 1983),
bile  duct  development  (Antoniou,  2009) and  skeleton  formation  (Foster,  1994).
Aberrant  expression  of  Sox9  leads  to  a  number  of  developmental  defects  and
diseases. 
SOX9’s implication in cancer has also been intensively explored. However, its
role in cancers seems controversial. It has been reported to be oncogenic in colon
cancer (Blache, 2004), prostate cancer (Wang, 2008) and lung cancer (Jiang, 2010).
Its interaction with TGF-beta, p63, WT-1, FGFR, and Hedgehog signaling renders
SOX9 aggressive in breast cancer (Katoh, 2008; Moore, 2008; Xu, 2009; Zardawi,
2009).  It  inhibits  PKC-alpha  in  the  intestine  epithelium to  promote  proliferation
(Dupasquier, 2009). 
On  the  contrary,  other  studies  indicated  an  anti-oncogenic  characteristic  of
SOX9. A study shows that promoter hypermethylation and thus loss of expression of
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SOX9 is associated with progression of bladder cancer (Aleman, 2008). SOX9 also
induces apoptosis in colon cancer cells (Jay, 2005) and inhibits colon cell growth by
negative regulation of Wnt/beta-catenin signaling (Blache, 2004). In melanomas and
retinoid-treated  breast  cancer  cell  lines,  Sox9  also  exerts  the  anti-cancer  effect
(Muller,  2009;  Afonja,  2002;  Passeron,  2009).  Other  evidence  includes  that  its
expression inhibits  oncogenic protein CEA in colon cancer  cells  (Jay,  2005) and
upregulates tumor suppressive CEACAM1 in normal intestine epithelium (Zalzali,
2008).
Regarding  its  implications  in  cancer  metastasis,  a  recent  publication
demonstrated that  cytoplasmic localization of  SOX9 promoted breast  cancer  cell
proliferation  and  correlated  with  poor  prognosis  of  invasive  breast  cancer
(Chakravarty,  2011).  Interestingly,  a  research group pointed out  that  there was a
spliced form of SOX9, named miniSOX9 (Abdel-Samad, 2011). It acted as SOX9
inhibitor  to  activate  Wnt/beta-catenin  signaling.  The  differential  expression  of
miniSOX9 in tumorous and normal colon tissues suggested its oncogenic feature. 
However, except for a study revealing that differential methylation of SOX9
promoter contributes to angiogenesis and higher metastatic potential in pancreatic





(1) There  would  be  some  metastasis  suppressor  genes,  whose  loss  of  function
would result in pancreatic cancer metastasis;
(2) There  would  be  gemcitabine  sensitivity  genes  existing,  down-regulation  of
which was responsible to gemcitabine resistance in PDAC.
Our objectives were to
(1) Identify metastasis suppressor genes in human PDAC;
(2) Investigate into cellular functions of the genes and understand
how they modulate pancreatic cancer cell metastasis;




Mammalian Cell Culture 
HPDE, Capan-2, SW1990, Bxpc3, Panc1, CFPAC1 and Panc0403 cells were
obtained from the American Type Culture Collection (Rockville, MD, USA). HPDE
was  cultured  in  Keratinocyte  Serum  Free  Medium  (KSFM)  (Gibco,  USA)
supplemented with L-glutamine, EGF, and BPE. Other cell lines were cultured in
Dulbecco’s  modified  Eagle’s  medium  supplemented  with  50  unit/ml  penicillin-
streptomycin (GibcoBRL, USA) and 10% (v/v) fetal bovine serum (Hyclone) in a
humidified  incubator  at  37°C  in  5%  CO2.  After  the  cells  reached  about  80%
confluence, the medium was removed and the cells were trypsinized with 1 ml of
0.05%  trypsin-EDTA  (Gibco,  USA  )  for  2  mins.  Then  cell  suspension  was
transferred to a 15-ml centrifuge tube containing 10 ml of PBS and centrifuged at
1,000 rpm at room temperature for 5 min. The cell pellet was resuspended with fresh
medium and transferred to new plates and incubated as described above. 
MTT Assay
MTT  (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide  was
purchased from USB Chemicals Corporation. The MTT powder was dissolved in
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sterile Nano-Pure water to a final concentration of 5mg/ml and sterilized by passage
through a 22 µm pore PVDF filter. Before treatments, 1x103 to 5x103 cells were
plated on a 96-well plate. When the treatment was completed, the cells were cultured
in  a  medium containing  1mg/ml  of  MTT for  3  more  hours.  Following that,  the
medium was discarded and 100 µl of DMSO was added to the wells  in 96-well
plate.  The  plate  was  shaken  at  a  speed  of  120  rpm  for  15  minutes.  Finally,
absorbance was measured at λ490nm. For each treatment, the samples were repeated
in triplicates.
Colony formation assay
One  thousand  cells  were  seeded  in  a  100mm  culture  dish.  Colonies  were
allowed to form for 2 weeks. Medium was changed very 3-4 days. Two weeks later,
culture medium was removed and the plate was rinsed with PBS twice. Colonies
were fixed by 100% methanol for 10 min and stained with coomassie blue for 5 min.
Total  number  of  colonies  formed  was  manually  counted  by  the  naked  eye
examination.
Wound healing assay
Cells were cultured in a 6-well plate to be confluent monolayer. A wound was
generated  by  gently  scratching  a  line  through  the  cells.  Cells  were  allowed  to
migrate  through  the  wound  for  72  hours.  The  boundaries  of  the  wound  were
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recorded every 24 hours under a microscope and the area of cell-free region was
calculated by Image J. 
Transwell migration chamber assay
Migration  was  accessed  using  a  24-well  format  cell  culture  insert  (SPL)
containing a polycarbonate membrane filter with 8 um pores. The upper chamber
contained cells in DMEM without FBS, and the lower chamber contained DMEM
plus 10% FBS as chemoattractant. Cells were incubated for 24 hours at 37°C in 5%
CO2 air.  Non-migrated cells were scraped off the upper surface of the membrane
with a cotton swab. Migrated cells remaining on the bottom surface were counted
after staining with crystal violet. 
Immunocytochemistry
In Day 1, appropriate amount of cells, treated or non-treated, were seeded on a
poly-L-lysine coated coverslips in a 96-well  plate and incubated in a humidified
incubator at 37°C overnight to allow the cell to attach the coverslip. In Day 2, the
cells were firstly washed with ice cold PBS twice and fixed in 4% paraformaldehyde
in PBS for 15 minutes at room temperature. After washing with PBS twice, 10ml
PBS containing 0.25% Triton X-100 was added to the cells for permeabilization.
The cells were washed in PBS 3 times for 5 minutes before incubation with primary
antibodies at 4°C overnight. The primary antibodies were diluted in a concentration
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suggested by the manufacturer. In day 3, the primary antibodies were discarded and
the cells were washed with ice cold PBS for 3 times. Then the cells were probed
with corresponding secondary antibody in dark for 2 hours. Finally, the cells were
counter stained with DAPI for 5 minutes and mounted on a slide with a drop of
ProLong® Gold anti-fade reagent (Invitrogen).
Transient transfection of siRNA
DharmaFECT  was  purchased  from  Thermo  Scientific.  The  transfection
procedure was done according to the product protocol.  In brief,  3000 cells  were
plated to each well of a 96-well plate and cultured in a 37°C overnight. On the next
day, 5 µl of 2 µM siRNA was mixed with 5 µl of plain DMEM medium in a 1.5-ml
eppendorf tube. In a separated tube, 0.5 µl of DharmaFECT transfection reagent was
added to 49.5 µl of plain DMEM. The mixtures were gently mixed by pipetting up
and down which were followed by 5 minutes of incubation at room temperature. The
diluted  siRNA was then added to the  diluted DharmaFECT transfection reagent,
mixed and incubated for another 20 minutes. When incubation was completed, 80 µl
of  antibiotic-free complete  medium was added to the mixture for a  final  siRNA
concentration of  100 nM. The medium from the  wells  of  the 96-well  plate  was
removed and replaced by the 100 µl transfection mixtures. Transfection medium was
replaced with fresh culture medium 8-16 hours post transfection.  The cells  were
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incubated at 37°C for additional 24 to 72 hours before harvest. Drug treatment could
start 24 hours after transfection.
Establishment of in-vivo and in-vitro models
shRNA library introduction
A total of 2 * 106 capan-2 cells were transfected with one vial of the lentiviral
human  50K  shRNA  library  (SBI,  SI206B-1)  by  polybrene  according  to  the
manufacturer’s  instruction.  3  days  after  transfection,  cells  were  subjected  to
puromycin selection at the concentration of 0.5 µg/ml for 8 days. Then cells were
applied  for  different  screening  schemes  for  the  enrichment  of  a  phenotype  of
interest.  After  harvest  of  cells  selected,  total  RNA was  isolated  and cDNA was
reverse  transcribed.  The  shRNA  templates  were  retrieved  according  to
manufacturer’s  instruction,  either  by  sequence  analysis  or  microarray  analysis.
Target genes of corresponding shRNAs could be identified according to a gene list
provided by manufacturer.
Establishment of the orthotopic pancreatic cancer mouse model
Male nude mice of 4 to 6 weeks old were supplied by the Laboratory Animal
Services Center (LASEC) of the Chinese University of Hong Kong (CUHK). They
were  housed  in  pathogen-free,  air-controlled  conditions  supplied  with  water,
bedding,  and  gamma-ray-sterilized  food,  with  12-hour  light-dark  cycles.  Right
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before tumor implantation, pancreatic cancer cells were trypsinized and resuspended
at  a  concentration  of  5,000,000  cells  per  50  µl  in  sterile  PBS  containing  10%
matrigel (BD) and were kept on ice until implantation. Mice were anesthetized using
ketamine/xylazine cocktail which was administrated by intraperitoneal injection at
10 µl per gram body weight. The cocktail was prepared by diluting 1 ml of ketamine
stock (20 mg/ml) and 0.5 ml xylazine (100 mg/ml) into 8.5 ml PBS under sterile
condition. 5-10 minutes after anesthetization, mice were positioned to the right. The
surface  of  the  abdomen  was  scrubbed  three  times  by  70%  ethanol.  After
confirmation of thorough anesthetization, an approximately 1 cm incision was made
and the pancreas was gently pulled out. 50 µl of cancer cell suspension was injected
into the tail of the pancreas by a 27 gauge needle. Two minutes after injection, the
pancreas was gently put back into the abdominal cavity. Three sutures were made
across the incision. After tumor transplantation, mice should be monitored daily for
signs of illness and for infections through the surgical wounds. 2 to 3 months after
transplantation,  mice  could  be  sacrificed  for  examination  of  tumor  growth  and
formation of metastasis. All experiments were approved by the Animal Experimental
Ethics Committee of the CUHK.
Package of lentivirus expressing shRNA
Lentivirus-based  shRNA vectors  targeting  SOX9 were  purchased  from abm
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(USA).  Lentivirus  was  produced  by  co-transfection  of  packaging  plasmids  and
shRNA plasmids  into 293T cells  using calcium phosphate methods.  Transfection
medium was changed 16 hour later and 293T cells were incubated for additional 72
hours. Supernatant was harvest after discarding the cell debris and was applied for
overnight centrifugation at 4°C for 7680 rpm. The viral pellet was resuspended in a
small volume of TBS buffer and kept at -80 °C.
Generation of stable cell line expressing shRNA
Capan-2 cells were cultured in a 24-well plate at 70% confluence. Optimized
volume  of  lentiviral  particles  was  added  into  the  cells  together  with  polybrene.
Transfection  medium  was  changed  the  next  day.  3  days  after  transfection,
correspondent selection agent could be given for an additional 2 weeks for selection
of cells stably expressing lentiviral constructs.
DNA manipulation 
Large scale plasmid isolation from E. coli (maxi-prep) 
QIAGEN Plasmid Maxi Kit (Qiagen, Germany) was used for plasmid DNA
preparation. An overnight culture of transformed E. coli in 500 ml of LB medium
with  appropriate  antibiotic  was  centrifuged  at  5000  rpm  for  15  minutes.  The
supernatant was discarded and the pellet was resuspended in 10 ml of buffer P1. To
lyse  the  cells,  10  ml  of  buffer  P2  was  applied  to  the  resuspended  culture  and
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incubated at  room temperature for 5 minutes.  To neutralize the lysate,  10 ml  of
buffer P3 solution was added into the lysate, followed by incubation on ice for 5
minutes.  The  cell  debris  was  separated  from  the  plasmid  DNA  solution  by
centrifugation at 7830 rpm for 30 min at 4°C. 10 ml of buffer QBT was added to the
Maxi-prep column to activate the resin. After the N3 has gone through the column,
the cell lysate from above was poured into the column until all of the lysate was
drawn through the resin by gravity. To wash the DNA-bound resin, 30 ml of buffer
QC was added to the column and allowed to empty by gravity, twice. To elute the
DNA from the resin, 15 ml of buffer QF was loaded to the column. Following that,
the eluent was mixed with 10.5 ml of isopropanol by inversion. To collect the DNA,
the solution was centrifuged at 15,000 rpm for 30 min at 4°C. The supernatant was
then discarded and the DNA pellet was washed with 1 ml of 70% ethanol, air-dried
at  room  temperature  and  resuspended  with  500  µl  of  TE  buffer.  The  DNA
concentration was measured by OD260. 
Analysis of Protein
Preparation of protein cell lysates
After the medium was discarded, the cells were washed with chilled PBS twice.
Then appropriate amount of cell  lysis  buffer (RIPA) supplemented with protease
inhibitor mixture was directly added to the cells and left it at 4 ºC for 15 minutes.
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The  lysed  cells  were  scraped  off  from  the  plate  and  transfer  to  a  1.5  ml
microcentrifuge  tube.  After  30  minutes  incubation  on  ice,  the  samples  were
centrifuged at 13,000 rpm for 30 minutes at 4°C to remove the insoluble cell debris.
The supernatant was collected and transferred to a new microcentrifuge tube.
Protein concentration determination 
Bicinchoninic  acid  (BCA)  protein  assay  system  was  used  to  measure  the
protein concentration of cell lysates. Firstly, 2 µl of protein samples were loaded into
a 96-well plate together with a series of standards consisting of 0, 2, 4, 8, 16 µg of
BSA.  Then 200 µl of BCA reagent A and 4 µl of BCA reagent B were mixed with
the samples and incubated at 37°C until the color of the mixture changed. At the
end, absorbance was measured at OD460. The readings of the BSA standards were
plotted with linear regression as a reference, and the concentration of the sample was
deduced by referring the reading of the protein sample to the BSA reference. 
SDS-PAGE 
Cell  lysates  were  suspended  in  Proteins  in  Laemmli  sample  buffer  to  a
concentration of 1 µg/µl and incubated at 100 ºC for 10 minutes. After that, the cell
lysates were separated in 10% or 15% polyacrylamide gels. The separating gel was
mixed with 40 µl of APS and 4 µl of TEMED, and allowed to polymerize at room
temperature. To prepare the stacking gel, 3 ml of stacker solution was mixed with 30
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µl of APS and 3 µl of TEMED. The stacking gel mixture was subsequently loaded
on top of the polymerized separating gel with 14-well comb inserted. The comb was
removed after the stacker was solidified. The gel was then assembled to the Mini-
PROTEAN Electrophoresis System (Bio-Rad). SDS-PAGE running buffer was then
filled into the tank. 10 µg of cell lysates were loaded into the wells and separated by
a constant voltage of 100 V for 100 minutes. 
Immunoblotting (Western blotting) 
The  Mini  Trans-Blot  (Bio-Rad)  was  used  to  transfer  proteins  from
polyacrylamide gels to PVDF membranes (Pall, USA). First of the all, the gel holder
cassette, with the black plate faced down, was put into a tank of transfer buffer. A
piece of foam pad was placed on the top of the black plate with a piece of 3MM
paper (Whatman, UK) was soaked in transfer buffer on it. The polyacrylamide gel
and a PVDF membrane were placed on top of the 3MM paper. At the end, another
piece of 3MM paper and foam pad was placed on the top of the membrane. The gel
holder cassette was closed and put into the modular electrode assembly. The transfer
was carried out at a constant voltage of 100V for 100 minutes. 
After the transfer, the membrane was soaked in 3% milk in TBST or 5% w/v
BSA in  TBST  for  30  minutes  to  block  non-specific  protein-binding  sites.  The
membrane was then incubated in 2% milk in TBST containing the primary antibody
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at the appropriate dilution at 4°C with shaking overnight. On Day 2, the membrane
was  washed  twice  with  TBST  for  15  minutes  each.  The  membrane  was  then
incubated in 3% milk or 2% w/v BSA in TBST containing the secondary antibody
conjugated with horse reddish peroxidase (Santa Cruz) at a dilution of 1:1000 at
room temperature for 2 hours. Finally, the membrane was washed three times with
TBST for 10 min each, incubated in ECL solution (Millipore USA) for 3 minutes,
put between two pieces of plastic film, and exposed to light sensitive films (Fuji,
Japan). The exact exposure time varied depending on the intensity of the signals.
The films were developed with a film-processing machine (Eastman Kodak, USA). 
RNA manipulations 
RNA Isolation
TRIzol® Reagent (Invitrogen) was used for RNA isolation. The samples, tissue
or cells, were firstly homogenized with Trizol and incubated at room temperature for
5  minutes.  For  1ml  of  Trizol  reagent,  200  µl  of  chloroform was  added  to  the
homogenized samples,  which was followed by vigorous shaking for 15 seconds.
After another 3 minutes of incubation, the samples were centrifuged at 12,000 × g
for 15 minutes at 4°C. Then, the top aqueous phase of the sample was transferred to
a new tube. 500 µl of 100% propanol was added to the aqueous phase. The mixture
was then incubated at  room temperature for 10 minutes which was followed by
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another centrifugation at 12,000 × g for 10 minutes at 4°C. The supernatant was
removed and 1 ml of RNase free 70% ethanol was added. After a brief vortexing, the
samples were centrifuged at 7500×g for 5 minutes at 4°C. The wash was discarded
and the RNA pellet was air dried. An appropriate amount of RNase free water was
used to  dissolve  the  RNA whose concentration  was subsequently determined by
NanoDrop (Thermo Scientific).
Synthesis of cDNA from RNA and quantitative PCR
The  synthesis  of  cDNA from  RNA used    High  Capacity  cDNA Reverse
Transcription Kit (Invitrogen). Firstly, 1 µg of purified RNA was added to RT buffer
(1x RT buffer, 4mM dNTPs, 1x RT random primers, reverse transcriptase and RNase
inhibitor) as provided to the final volume of 25 µl. After a gentle mixing and a short
spin down, the sample was placed in a thermal cycler with a program set according
to manufacturer’s guideline. 
The  relative  expression  level  of  genes  was  determined  by  using  semi
quantitative  PCR.  1  µl  of  the  cDNA obtained from previous  step was added to
Power SYBR® Green PCR Master Mix (Invitrogen) containing corresponding set of
primers for gene detection. Then  the samples were loaded in triplicated into a 96-
well or 384-well plate which was then placed in ABI 7900HT Fast Real Time PCR
for  measuring  the  CT  values.  The  relative  expression  level  of  each  gene  was
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determined by comparative quantization.
Analysis of Clinical Samples
Clinical specimens
Pairs  of  pancreas  normal  and tumor  tissues  were  collected  from pancreatic
cancer patients in  Prince of Wales Hospital,  Hong Kong. Samples were fixed in
3.7% paraformaldehyde for 24 hours, embedded in paraffin and sectioned as 5 um
onto glass slides.
Immunohistochemistry
Histostain®-Plus Kits was used for immunohistochemistry. First of the all, the
samples were deparaffinized and rehydrated by immersing the slide in following
solutions and order:  twice in xylene for 5 minutes,  twice in 100% ethanol for 5
minutes, once in 90% ethanol for 3 minutes, once in 80% ethanol for 3 minutes,
once in 70% ethanol for 3 minutes and finally in 1X PBS for 1 minutes before
drying the slide. To inactivate endogenous peroxidase, the samples were incubated
with 3% H2O2 in methanol for 5 minutes. 100 µl of serum blocking solution was
applied the sample for 10 minutes to block non-specific antibody binding sites. The
primary was diluted in  appropriate  concentration and applied to  the sample in  a
humidified  chamber  at  4  °C  overnight.  In  next  day,  the  primary  antibody  was
removed by rinsing in PBS twice. 100 µl of biotinylated secondary antibody was
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added to each section and incubated for minutes. Sequentially, 2 drops of Reagent C
was added to the sections for conjugating the streptavidin-peroxidase. At the end, the
sample was covered with DAB to develop the signal. A light haematoxylin stain was
applied as counterstain.
Measurement  of  IHC  staining  was  based  on  a  semi-quantitative  scoring
method. For the percentage (P) of positively stained cancer cells, 0 = less than 10%,
1 = 10-50%, 2 = 50-75%, 3 = more than 75%. For the intensity (I) of staining, 0 =
negative,  1  = weak,  2  = moderate,  3  = strong.  By multiply P and I,  the  scores
spanned from 0 to 9, where “-” = 0, “+” = 1-2, “++” = 3-4, and “+++” = 5-9. Both
“–” and “+” were identified as negative and both “++” and “+++” were identified as
positive. For statistical analysis of IHC scores, Mann-Whitney non-parametric test
was applied.
Results
Genome-wide RNAi screening identifies genes as metastasis suppressor
s in an orthotopic pancreatic cancer mouse model
In order to identify genes that play critical roles in pancreatic cancer metastasis,
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we  conducted  an  in  vivo  whole  genome  screening.  We  used  a  genome-wide
lentiviral-based shRNA library (SBI) as a powerful tool which facilitated the high-
throughput functional genomic studies. This library comprises of a pool of shRNAs
(3-5 shRNA constructs per target gene) targeting 47,400 human transcripts. It can be
introduced  into  a  population  of  identical  cells.  Because  the  library  is  lentivirus
based, the shRNA constructs can be highly efficiently integrate into genomic DNA
of target cells. The endogenous and heritable expression of shRNA effectors in target
cells guarantees long-term stable silencing of target gene for subsequent functional
studies. And then cells containing the whole library can be applied for screening of a
phenotype of interest. Cells of a selected phenotype can be harvested and the shRNA
constructs inducing this phenotype can be retrieved. 
Figure 11A demonstrates the strategy of our screen. To begin with, the library
was transduced into capan-2 cells. As a human PDAC cell line, capan-2 is capable of
forming tumors in nude mice and is previously reported possessing low metastatic
potential to the liver (Suemizu, 2007). The reason why this cell line was chosen for
the screening is based on our hypothesis that knocking down a metastasis suppressor
gene will enable the metastasis-defective cells to spread out. The transduction of the
library was carried out at low multiplicity of infection (MOI) to ensure that each cell
acquired  only one  unique  shRNA inserts.  Following  the  infection,  capan-2  cells
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were selected in puromycin for 2 weeks, for the purposes that, on one hand, a pure
population  of  transduced  cells  were  obtained,  and  on  the  other  hand  cells  with
shRNAs targeting vital genes were excluded.
After  puromycin  selection,  capan-2  cells  bearing  the  entire  library  were
transplanted into nude mice to perform the in vivo screen. Our in vivo screening
system was established based on an orthotopic pancreatic cancer model. By surgical
operations,  cancer  cells  were  directly  inoculated  into  mouse  pancreas  where
pancreatic cancer normally grew. The orthotopic model, instead of a subcutaneous
model or a tail vein injection model, exhibits some advantages. Firstly, the primary
site of tumor growth provides the microenvironment that best mimics the generation
a  spontaneous  pancreatic  cancer.  Secondly,  tumor  cells  in  the  pancreas  must
overcome  all  metastatic  suppressing  programs  and  complete  all  of  the  steps  of
metastasis to spread to other parts of the body. Here mice were serves as a selection
system or a cell sorter to detect successfully metastasized cells. Given that liver was
the  most  common  site  of  pancreatic  cancer  metastasis,  we  mainly  focused  our
attention on liver metastasis.
About two to three months after transplantation, mice would be sacrificed for a
careful examination. Tumor nodules in the liver would indicate the occurrence of
liver metastasis. We supposed that each liver nodule derived from a single pancreatic
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cancer cell and that silencing a particular gene in the cell allowed it to spread out.
Then the nodules could be harvested for the recovery of their  shRNA templates,
whose expression was supposed to induce metastasis. Finally the target gene of the
shRNA could be decoded by sequencing analysis. Thus the gene could be identified
as a metastasis suppressor gene.
In the primary screening, we used 25 nude mice for the screening. As shown in
figure 11B, all of them had primary tumors grown after injection of capan-2 cells
into their pancreas. Six of them generated liver metastasis in 8 to 12 weeks. The
shRNAs retrieved from the metastatic liver nodules corresponded to SOX9, ABCE1,
BLVRB, CNDP2, SYNJ1, and TPST2. Subsequently we carried out experiments for
the  validation  of  these  candidate  metastasis  suppressor  genes.  In  this  study,  we
mainly focused on SOX9.
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Figure 11.
Figure 11: Genome-wide in vivo screening for metastasis suppressor genes
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(A) The strategy of the genome-wide screening in an orthotopic pancreatic cancer
mouse model. Details are described in the text.
(B) Primary tumors generated in all 25 nude mice in the initial screen. Six of them
developed liver metastasis  in  8 to 12 weeks.  Arrows indicate primary pancreatic
tumor and liver metastatic nodule. Retrieving shRNA constructs from liver nodules
together  with  sequencing  analysis  revealed  6  genes  as  candidate  metastasis
suppressors, such as SOX9.
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SOX9 is a metastasis suppressor gene in pancreatic cancer
To  validate  SOX9’s  anti-metastasis  effect  on  pancreatic  cancer,  we  firstly
generated  stable  capan-2  cell  lines  that  endogenously  expressed  SOX9 shRNAs
through lentiviral infection techniques. Four shSOX9 constructs (a, b, c, and d) were
tested in this study. The knockdown efficiency of SOX9 in these cell lines were
double confirmed in mRNA level and protein level (figure 12A). Regarding to the
knockdown efficacy, the stable cell line expressing shSOX9-a and its control cell
line expressing shLUC were used in following experiments. 
ShSOX9 and  shLUC capan-2  cells  were  injected  into  the  pancreas  of  two
groups of nude mice using the same methods as in the initial screening (figure 12B).
Twelve weeks after transplantation, mice were sacrificed to examine primary tumor
growth  and  the  presence  of  metastasis.  Pancreatic  tumors  were  successfully
established in the primary site for all mice in both groups. Basically, the growth of
primary tumor showed no difference between SOX9 knockdown (Kd) group and
control  groups  (data  not  shown).  However,  different  status  of  liver  metastasis
between the two groups was found. Metastatic liver nodules occurred in 7 out of 11
mice in SOX9 Kd group, while only 2 out of 10 mice were found with liver nodules
in  control  group.  It  indicated  that  the  probability  of  the  occurrence  of  liver
metastasis was significantly higher in SOX9 Kd group than that in control group
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(figure 12B and C). It meant that down-regulation of SOX9 promoted capan-2 cells
to  spread to  the liver.  Moreover,  the number of metastatic  nodules  was more in
SOX9 Kd group (totally 10 nodules for 11 mice) than in control group (totally 3
nodules for 10 mice).  In regards to the size of metastatic tumors, liver nodules of
shSOX9 group were larger in size (figure 12D), which further supported the notion
that silenced expression of SOX9 enhanced capan-2’s ability to metastasize to the
liver.  Finally,  histological  analysis  of  liver  sections  confirmed  the  cells  of  live
nodules  were  from  primary  pancreatic  tumor  (figure  12E).  In  conclusion,  this





Figure 12: Validation of SOX9 as a metastasis suppressor gene in pancreatic 
cancer.
A. Capan-2  stable  cell  lines  expressing  shSOX9  or  control  shLUC  were
generated by lentiviral  transduction.  The expression levels of SOX9 were
confirmed at both mRNA and protein levels. The shSOX9-a and shLUC cell
lines were chosen for subsequent experiments.
B. Knocking-down of SOX9 promoted the orthotopically transplanted capan-2
cells  to metastasize to the liver.  In the validation experiments, 10 and 11
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nude  mice  were  used  for  control  shLUC  group  and  shSOX9-a  group
respectively. All of them had primary tumors established. 7 out of 11 mice in
shSOX9  group  developed  liver  metastasis,  whereas  only  2  out  of  10
metastasized in control group. Primary pancreatic cancer and the liver of the
representative mice are shown. Arrow points at metastatic tumor nodules in
the liver.
C. Probability  of  liver  metastasis  derived  from pancreatic  cancer  in  control
group  (n=10)  and  SOX9-knockdown  group  (n=11).  The  probability  was
significantly higher in SOX9-knockdown group than that in control group.
D. Liver metastatic nodules of shSOX9 group were larger in size and greater in
number, compared with control group.
E. H & E staining of liver sections confirmed the cells in liver nodules were
from primary pancreatic tumor.
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Investigation into cellular functions of SOX9
To study the potential mechanisms of SOX9 as a metastasis suppressor gene,
we evaluated SOX9’s effect on the following aspects, for example, cell proliferation,
colony formation, and migration, which are relevant features of metastasis.
SOX9’s effect on cell growth
It is proposed that genes exclusively regulating metastasis do not exist and that
genes play a role in metastasis also affect tumor growth (Duffy, 2008). It has been
suggested that the capability for cancer cells to metastasize are acquired from the
very beginning  of  tumor  formation  (Bernards,  2002).  This  point  of  view seems
reasonable, because genes that favor cancer cell proliferation may provide growth
advantages for the metastatic tumors to survive in a distant location. 
Based  on  these  theories,  we  firstly  examined  whether  the  metastasis
suppressive  SOX9 had  any effects  on  tumor  growth.  MTT assays  revealed  that
down-regulation  of  SOX9  did  not  remarkably  enhance  pancreatic  cancer  cell
proliferation in vitro (Figure 13A). 
Then we performed colony formation assay to explore whether SOX9 affected
cancer cells’ ability to form colonies. This assay tests the ability of every single cell
in a certain population to grow into a colony. In a highly diluted seeding condition, a
cell must initiate unlimited division to give rise to a colony. Only a proportion of
cells seeded possess this ability (Franken, 2006). In our studies, SOX9’s effect on
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this process was not obvious (figure 13B). In each 100mm culture dish, 1000 cells of
each cell line were seeded. 2 weeks later, the numbers of cells to form colonies were
not significantly different between SOX9 Kd and control groups. Thus in this case
we failed to prove that the enhanced metastatic potential of pancreatic cancer cells
was due to increased colony formation capability that supported a wandering tumor
cell to colonize in a distant organ.  
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Figure 13.
Figure 13: SOX9’s effect on cell growth
(A)MTT assays  showed  that  down-regulation  of  SOX9  did  not  remarkably
enhance cell proliferation. (*, P < 0.05 at day 4)
(B) Colony formation assay showed no significantly difference in the capability
of colony formation between SOX9 Kd and control cells. 1000 cells were
seeded in a 100 mm dish. 2 weeks later, colonies derived from the cells seed
were detected by coomassie blue staining. 2 independent experiments with
duplicates  were  performed.  Representative  plates  of  the  assay  were
demonstrated.
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SOX9’s effect on cell migration
High migratory and invasive activity of cancer cells is  closely correlated to
metastasis. Invasive capability is the major feature to distinguish malignancy from
benign  lesions.  During  invasion,  proteases  produced  by  malignant  cells  digest
extracellular  matrix  and  neighboring  tissues.  The  breakdown  of  tissue  barriers
facilitated  cell  motility.  Besides,  migration  behavior  is  essential  for  a  metastatic
cancer  cell  in  the  process  of  intravasation  and extravasation  to  blood vessels  or
lymphatic system. It has been realized that molecules involved in these processes
may be future targets of cancer therapy to prevent metastasis  or suppress cancer
progression. To access SOX9’s contribution to cell migration and invasion, capan-2
cells expressing either shSOX9 or control shLUC were subjected to wound healing
assay, trans-well chamber assay and matrigel invasion assay.
For wound healing assay,  a wound was generated by gently drawing a line
through a confluent mono-layer of cultured cells using a 200ul pipette tip. Cells of
higher migration potential would intend to fill the gap. Real time records of cells on
the boundaries revealed that the scratched area was shrunk faster in cells transduced
with  shSOX9  (figure  14A).  Actually,  both  cell  proliferation  and  migration  are
crucial factors affecting the healing of a wound. Given that SOX9’s expression did
not significantly contribute to cell growth as shown in figure 13, the efficient healing
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of  SOX9 Kd cells  we observed  could  be  regarded  solely  due  to  cell  migratory
activity.  Thus  we  reasoned  that  down-regulation  of  SOX9  enhanced  pancreatic
cancer cells migration. 
Trans-well chamber assay also evaluated migratory capability cells. With 10%
FBS as chemo-attractant, cells capable of migrating are able to move across the 8
um pores in the membrane, while cells without migratory activity stay unchanged.
As demonstrated in figure 14B, 24 hours after assay started, approximately 3 times
more cells migrated through the pores in shSOX9 group than that in control group,
indicating silenced expression of SOX9 endowed the low metastatic potential capan-
2 cells with migration ability. 
We  also  assayed  invasion  capability  for  these  cells  but  failed  to  obtain
meaningful results. Neither control nor SOX9 Kd capan-2 cells invaded the coated
matrigel above the membrane of the chamber upon 10% FBS attraction. Probably
down-regulation  of  SOX9 was  not  powerful  enough  to  trigger  capan-2  cells  to
invade. Other possibility is that SOX9 is not relevant to cell invasion. 
In general, we found that down-regulation of SOX9 enhanced capan-2’s ability
to migrate in vitro, but did not significantly promote cell growth, which provided
supportive evidence for SOX9 to be a metastasis suppressor gene.
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Figure 14.
Figure 14: Down-regulation of SOX9’s enhanced cell migration.
(A)Wound healing assay showed that cells with SOX9 knocked-down moved
faster to fill the gap. Images of the wound were taken at 0, 24 and 48 hours
after the wound generation. The area of the wounds was quantified by Image
J and normalized to 0 hour. Two independent experiments with triplicates
were conducted. Representative images were shown. *, p < 0.05.
(B) Transwell chamber assay also use for analyzing cell migration capability. 5 *
104 cells were seeded in the upper chamber of a cell culture insert with 8 µm
pores.  Inhibited  expression  of  SOX9  promoted  capan-2  cells  to  migrate
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through the pores within 24 hours. Numbers of cell migrated were counted in
each view captured under microscope. Three independent experiments with
triplicates were carried out. Representative images were shown. P = 0.002.
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Implication of SOX9 in human pancreatic cancer samples
To further  investigate  SOX9’s  importance  in  metastatic  status  of  pancreatic
cancer,  we examined expression level of SOX9 in 29 human primary pancreatic
tumors samples. They were from patients diagnosed as pancreatic ductal carcinoma
in Princess of Wales Hospital for the past ten years. The samples were collected
during  surgical  resection,  with  known  distant  metastatic  status  by  follow-up
observations. Patients of 14 samples had identified distant metastatic sites. Among
the 14 cases, 7 metastasized to the liver, while other 7 carried metastatic sites of
peritoneal, abdominal cavity, pelvis cavity, distant lymph nodes, and bowel matting.
The other 15 samples had not shown any evidence of distant metastasis till the time
of data analysis. 
Expression of SOX9 in normal pancreatic tissue and primary pancreatic tumor
tissues  were  accessed  by  immunohistochemistry  (IHC)  staining.  As  the
representative  images  demonstrated  in  figure  15,  normal  pancreatic  duct  cells
expressed high basal level of SOX9, which is consistent with some published studies
(Furuyama,  2010;  Lynn,  Smith  et  al.  2007).  Intense  SOX9 stain  was  frequently
found in non-metastatic tumor samples. On the contrary, the majority of metastatic
tumor  samples  exhibited  weak  to  mild  SOX9  expression.  Through  quantitative
analysis  of  IHC  staining  (table  4),  10  out  of  15  non-metastatic  samples  were
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identified  as  positive  stain,  whereas  only  4  out  of  14  metastatic  samples  were
positive. This difference between groups was significant (p = 0.044). These results
confirmed  a  good  correlation  between  SOX9  expression  and  metastatic  status,




Figure 15: SOX9 expression in human pancreatic cancer samples and normal 
pancreatic tissues.
Primary tumor samples from 29 pancreatic cancer patients with known distant 
metastatic status were analyzed in this study. Immunostaining revealed SOX9 
expression was high in normal pancreatic tissue. Comparing primary tumor tissues 
of different metastatic status, there was substantially lower expression level of 
SOX9 in metastatic pancreatic tumor than in non-metastatic pancreatic tumor. 
Representative images are shown.
Table 4. Semi-quantitative analysis of SOX9 expression in human pancreatic 
cancer samples.
Semi-quantitative analysis  of  IHC staining of  29 pancreatic  cancer  samples.
IHC scoring  method  is  illustrated  in  methods  and  materials.  Statistical  analysis
indicated  a  significant  difference  of  SOX9  expression  between  non-metastatic
tumors and metastatic tumors.
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Genome-wide RNAi screening for the identification of gemcitabine sens
itivity genes 
Considering  the  profound  gemcitabine  resistant  problems  that  frustrated
medical care for pancreatic cancer for decades, we performed a genome-wide RNAi
in vitro screening with the purpose to identify critical genes whose inhibition could
render  pancreatic  cancer  cells  resistant  to  gemcitabine.  Figure  16  illustrates  the
scheme  of  the  screen.  The  same  cell  population  transduced  with  the  lentiviral
shRNA library as used in the previous screening was applied for this screen. Capan-
2 cells have been reported to be sensitive to gemcitabine (Giroux V, 2006). The cells
carrying the whole library were divided into two identical groups. For one of them,
RNA was immediately isolated without any drug treatment. The other sample was
then  subjected  to  2  uM  gemcitabine  treatment  for  6  days.  We  expected  that
knockdown of particular genes would induce capan-2’s resistance to gemcitabine.
After 6 days of culture with the presence of gemcitabine,  resistant clones would
grow and growth advantages provided by shRNAs would be amplified. At that time,
survival cells were harvested and RNA was isolated in the drug treated sample. Then
the  RNA  samples  of  before  and  after  gemcitabine  treatment  were  reverse
transcribed, and shRNA fragments were amplified by PCRs and labeled with biotin
probes. These biotin-labeled PCR products were ready to use for hybridization of the
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compatible  microarray  chips.  The  signals  of  the  gene  chip  represented  the
abundance of shRNAs in samples. By comparing the gemcitabine treated sample to
non-treated control sample, we may find shRNAs with increased fold of change as
resistant clones and the correspondent genes to be gemcitabine sensitivity genes.
After data analysis, we found 30 shRNAs with fold-of-change larger than 3-
fold (table 5). They were regarded as potential gemcitabine sensitivity genes. We
focused our attention on one of the genes, LLGL1. The validation experiments were
carried out to verify its function for gemcitabine resistance. Firstly, knockdown of
LLGL1 expression was achieved by transient transfection of siLLGL1 into capan-2
cells.  Quantitative  realtime-PCR confirmed  the  knockdown efficiency  of  all  the
three siRNAs (figure 17A). We picked siLLGL1-(1) for subsequent experiments due
to its significance. 24 hours after transfection of either siLLGL1 or negative control
siRNA, cells were given gemcitabine at different concentrations (2uM and 8uM) for
additional 72 hours. Cell proliferation was accessed by MTT assays.  Figure 17B
revealed  an  increase  of  cell  growth  in  LLGL1  suppressed  cells,  which  was
consistent  with  the  idea  that  inhibition  of  LLGL1  could  provide  resistance  to
gemcitabine treated cells. 
Moreover,  we investigated LLGL1 expression in  several  human PDAC cell
lines (Capan-2, SW1990, Panc04.03, CFPAC1, Bxpc3, and Panc1) and an immortal
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human pancreatic duct epithelial cell line HPDE. Varied expression level of LLGL1
could  be  seen in  different  cell  lines  (figure 18).  It  is  reported  that  capan-2 is  a
sensitive cell line to gemcitabine treatment, and BxPC3 and Panc-1 are resistant cell
lines(Giroux V, 2006). Their sensitivity to gemcitabine in order is: Capan-2 > Bxpc3
> Panc1. It was interested to found that LLGL1 expression levels in these cell lines
are Capan-2 > Bxpc3 > Panc1, which seemed to be a desirable correlation between
LLGL1 levels and gemcitabine sensitivity. In other words, the more sensitive a cell
line,  the  higher  level  of  LLGL1 expression  it  would  have.  This  finding  further
supported LLGL1 to be a gemcitabine sensitivity gene.
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Figure 16.
Figure 16: Scheme of an in vitro genome-wide screening for gemcitabine 
sensitivity genes.
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Table 5. Candidate gemcitabine sensitivity genes from primary screening.
List  of  candidate  gemcitabine  sensitivity  genes  identified  through  microarray
analysis. Genes are listed in descending order according to the fold of change of
individual shRNAs. The SD of fold of change of shRNAs in this screening was 1.27.
ShRNAs of greater than 3-fold changes are shown. 
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Figure 17.
Figure 17: Validation of LLGL1 as a gemcitabine sensitivity gene
(A)Knockdown  efficiency  of  LLGL1  by  transient  transfection  of  siRNA in
capan-2 cells.
(B) MTT assays  revealed that  down-regulation of  LLGL1 effectively induced
resistance of capan-2 to gemcitabine.
117
Figure 18.
Figure 18: LLGL1 expression in human PDAC cell lines and normal pancreatic
ductal cell line.
LLGL1 expression levels in PDAC cell lines were positively correlated with their
sensitivity to gemcitabine. Sensitivity of cells to gemcitabine: Capan-2 > Bxpc3 >
Panc1. Relative mRNA expression of LLGL1 was measured by qPCR for human
PDAC cell lines (Capan-2, SW1990, Panc04.03, CFPAC1, Bxpc3, and Panc1) and a
human pancreatic duct epithelial cell line HPDE. 
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4. Discussion
Metastasis is the major cause of cancer death and it is a complicated process.
To identify novel  metastasis  suppressor  genes,  we carried  out  a  forward  whole-
genome screening in a mouse model. 
To begin with our work, we firstly established an in vivo screening system,
which  was  based  on  an  orthotopic  pancreatic  cancer  mouse  model.  This  model
possesses advantages for many reasons. Firstly, pancreatic cnacer cells were directly
transplanted in the pancreas of a mouse. Thus the model best simulated the original
microenvironment  for  a  tumor  to  grow,  which  may  provide  substantially  more
valuable data and less false positive results than in vitro assays. Secondly, tumor
cells transplanted in the primary site should overcome all difficulties that suppress
metastasis to disseminate. The cell line we used in the screening was capan-2, which
was  of  low  metastatic  potential.  Therefore  capan-2  is  suitable  for  screening  a
metastasis suppressor gene, based on the rationale that knockdown of a metastasis
suppressor gene would facilitate cell metastasis. 
Using  a  genome-wide  loss-of-function  screenitng,  we  found  SOX9  as  a
potential metastasis suppressor gene. Through an in vivo validation experiment, we
proved that down-regulation of SOX9 enhanced the occurrence of liver metastasis of
pancreatic cancer with capan-2 cells.  This indicated that SOX9 was a metastasis
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suppressor gene for pancreatic cancer cell capan-2. 
Capan-2  is  of  low  metastatic  potential,  but  it  is  unclear  in  which  step  of
metastasis capan-2 is defective. Thus we have to investigate into SOX9’s effect on
various cellular functions that are relevant to metastasis. From the results we have
achieved, we found in vitro that knocking-down SOX9 promoted cell migration but
did  not  significantly  favor  cell  proliferation  or  colonization.  These  findings
suggested that  probably SOX9 suppressed  metastasis  through modulation  of  cell
migration. However, the mechanism underlying SOX9’s function in metastasis is far
from elucidated. The downstream target genes and signaling pathways of SOX9 that
play  a  role  in  cell  survival,  EMT,  invasion,  and  angiogenesis  may  also  affect
metastatic  activity.  Besides,  what  causes  SOX9  down-regulation  to  induce
metastasis still  remains to be explored. All of these aspects can be considered as
future directions.
Metastasis is a complex multi-step process. Difficulties in any steps within the
process  may prohibit  a  cancer  cell  to  grow in  a  distant  location.  Unfortunately,
current methods for the study of cancer metastasis are limited. Additionally, current
research  methods  we  used  to  evaluate  cellular  functions  mainly  relied  on  two-
dimensional  (2D) substrates.  But the real  environment  of metastasis  is  on three-
dimensional  (3D)  basis,  where  interplay  between  cancer  cells  and  extracellular
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matrix  is  important.  It  has  been  reported  that  some  cell  types  have  drastically
different performance between 2-D and 3-D environment (Fraley, 2011). Nowadays,
we are still in great need of appropriate approaches to study metastasis. If the cell
line used in the screening has a known defect during the processes of metastasis, the
results from the screening could provide a more specific answer for the mechanisms.
Admittedly, our screening and validation were conducted on a single cell line, which
was not convincing enough to show the function of SOX9 in human PDAC. Using
different  PDAC cell  lines  for  validation  will  provide much stronger  evidence to
prove SOX9 as metastasis suppressor gene in human PDAC. 
Fortunately,  we observed a  correlation  between SOX9 expression  level  and
metastatic status in clinical samples of pancreatic cancer patients. On the one hand,
we confirmed the relatively high expression level of SOX9 in normal pancreas duct
cells, which was concordant with data published by other research groups, implying
an important role of SOX9 in maintaining normal function of pancreas duct cells.
On the  other  hand,  we  observed  a  decreased  expression  of  SOX9 in  metastatic
PDAC compared to non-metastatic PDAC. This result implied that loss of SOX9
expression was relevant to the occurrence of pancreatic cancer metastasis, which
further  supported  our  statement  that  SOX9 was  a  metastasis  suppressor  gene  in
human PDAC.
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Regardless of the mechanisms of SOX9 in modulating metastasis, if a good
correlation between SOX9 expression level and metastatic status really exists, SOX9
may be  served  as  a  biomarker  as  well  to  predict  metastasis  and  prognosis  for
patients. However, in this situation, analysis of data from a larger sample pool is in
great need for the identification of SOX9 as a biomarker.
Last but not the least, in vitro genome-wide RNAi screening revealed a novel
gene  to  be  associated  with  gemcitabine  resistance  in  pancreatic  cancer  cells.
Although gemcitabine still stands for the first choice of chemotherapeutic agent for
PDAC,  the  noticeable  problems  derived  from gemcitabine  resistance  profoundly
impede  our  progress  in  improving  the  prognosis  of  pancreatic  cancer.  Current
research  into  the  mechanisms  of  gemcitabine  resistance  mainly  focuses  in  the
defects  through steps  involving in  gemcitabine uptake  or  metabolism.  Treatment
strategies  targeting  these  defects  have  shown  limited  effect  in  improving  the
outcome of PDAC. Considering this  difficult  situation,  we attempted to discover
novel genes responsible for gemcitabine resistance on a genome-wide scale. 
In  our  screening,  LLGL1 was  identified  as  a  gemcitabine  sensitivity  gene.
LLGL1 is similar to a tumor suppressor gene in Drosophila. It has been reported that
its  expression  is  lost  in  several  human solid  tumors  (Grifoni,  2004).  A research
group found that mutation of LLGL1 was frequently found in HCC and abnormal
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expression of LLGL1 was associated with poor HCC differentiation, larger tumor
size  and invasive  feature  (Lu,  2009).  But  little  literature  has  been published  on
LLGL1’s implication in human PDAC. Here we found that LLGL1 expression level
was positively correlated with PDAC cells’ sensitivity to gemcitabine. And we also
reported  down-regulation  of  LLGL1  rendered  capan-2  cells  more  resistant  to
gemcitabine. These results indicated LLGL1 to be the gemcitabine sensitivity gene
in pancreatic cancer. Admittedly, the effect of LLGL1 knockdown on gemcitabine
resistance that we obtained was far from satisfied. Possibly it is due to the unstable
knockdown effect of transient transfection of siRNA. And the fluctuated knockdown
efficiency limited the application of functional assays. We are going to generate a
stable cell line with LLGL1 knocked down for follow-up studies. On the other hand,
given the nature of microarray analysis, there were a large number of false positive
results, which disturbed our decision. Currently we only pick limited targets from
numerous  candidate  genes  to  perform  validation  experiments,  which  further
restrained  successful  validation.  Although  the  effect  of  LLGL1  knockdown  on
gemcitabine  resistant  was  modest,  it  still  provided  some new ideas  for  targeted
therapy in pancreatic cancer. 
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General conclusions
To summarize the two parts of my study, 
(1)  We have confirmed the anti-cancer  effect  of  Brucein  D on liver  cancer
through  both  in  vitro  and  in  vivo  experiments.  It  further  strengthened  BD’s
therapeutic potential for cancers.
(2) We proposed a possible mechanism for BD-modulated growth inhibition.
That  was  BD inhibits  miR-95,  then  results  in  restoration  of  CUGBP2 and  thus
induces apoptosis for HCC cells. The identification of miR-95 as a target of BD is
novel, which provided new insights into research of cancer therapy.
(3) We have identified SOX9 as a metastasis suppressor gene in a pancreatic
cancer mouse model with capan-2 cells. And we also observed a correlation between
SOX9 expression level and metastatic status of human pancreatic cancer. SOX9 may
serve  as  a  new  biomarker  for  pancreatic  cancer  prognosis  and  has  therapeutic
potential for human PDAC management.
(4) We suggested LLGL1 to be a gemcitabine sensitivity gene in PDAC. It may
be a novel therapeutic target for pancreatic cancer chemotherapy.
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